Patent Grant
11690976
This application generally relates to devices and methods for reducing left atrial pressure, particularly in subjects with heart pathologies such as congestive heart failure (CHF) or myocardial infarction (MI), and apparatus for delivering such devices.
Heart failure is the physiological state in which cardiac output is insufficient to meet the needs of the body and the lungs. CHF occurs when cardiac output is relatively low and the body becomes congested with fluid. There are many possible underlying causes of CHF, including myocardial infarction, coronary artery disease, valvular disease, and myocarditis. Chronic heart failure is associated with neurohormonal activation and alterations in autonomic control. Although these compensatory neurohormonal mechanisms provide valuable support for the heart under normal physiological circumstances, they also have a fundamental role in the development and subsequent progression of CHF. For example, one of the body's main compensatory mechanisms for reduced blood flow in CHF is to increase the amount of salt and water retained by the kidneys. Retaining salt and water, instead of excreting it into the urine, increases the volume of blood in the bloodstream and helps to maintain blood pressure. However, the larger volume of blood also stretches the heart muscle, enlarging the heart chambers, particularly the ventricles. At a certain amount of stretching, the heart's contractions become weakened, and the heart failure worsens. Another compensatory mechanism is vasoconstriction of the arterial system. This mechanism, like salt and water retention, raises the blood pressure to help maintain adequate perfusion.
In low ejection fraction (EF) heart failure, high pressures in the heart result from the body's attempt to maintain the high pressures needed for adequate peripheral perfusion. However, the heart weakens as a result of the high pressures, aggravating the disorder. Pressure in the left atrium may exceed 25 mmHg, at which stage, fluids from the blood flowing through the pulmonary circulatory system flow out of the interstitial spaces and into the alveoli, causing pulmonary edema and lung congestion.
Table 1 lists typical ranges of right atrial pressure (RAP), right ventricular pressure (RVP), left atrial pressure (LAP), left ventricular pressure (LVP), cardiac output (CO), and stroke volume (SV) for a normal heart and for a heart suffering from CHF. In a normal heart beating at around 70 beats/minute, the stroke volume needed to maintain normal cardiac output is about 60 to 100 milliliters. When the preload, after-load, and contractility of the heart are normal, the pressures required to achieve normal cardiac output are listed in Table 1. In a heart suffering from CHF, the hemodynamic parameters change (as shown in Table 1) to maximize peripheral perfusion.
CHF is generally classified as either systolic heart failure (SHF) or diastolic heart failure (DHF). In SHF, the pumping action of the heart is reduced or weakened. A common clinical measurement is the ejection fraction, which is a function of the blood ejected out of the left ventricle (stroke volume), divided by the maximum volume remaining in the left ventricle at the end of diastole or relaxation phase. A normal ejection fraction is greater than 50%. Systolic heart failure has a decreased ejection fraction of less than 50%. A patient with SHF may usually have a larger left ventricle because of a phenomenon called cardiac remodeling that occurs secondarily to the higher ventricular pressures.
In DHF, the heart generally contracts normally, with a normal ejection fraction, but is stiffer, or less compliant, than a healthy heart would be when relaxing and filling with blood. This stiffness may impede blood from filling the heart, and produce backup into the lungs, which may result in pulmonary venous hypertension and lung edema. DHF is more common in patients older than 75 years, especially in women with high blood pressure.
Both variants of CHF have been treated using pharmacological approaches, which typically involve the use of vasodilators for reducing the workload of the heart by reducing systemic vascular resistance, as well as diuretics, which inhibit fluid accumulation and edema formation, and reduce cardiac filling pressure.
In more severe cases of CHF, assist devices such as mechanical pumps have been used to reduce the load on the heart by performing all or part of the pumping function normally done by the heart. Chronic left ventricular assist devices (LVAD), and cardiac transplantation, often are used as measures of last resort. However, such assist devices are typically intended to improve the pumping capacity of the heart, to increase cardiac output to levels compatible with normal life, and to sustain the patient until a donor heart for transplantation becomes available. Such mechanical devices enable propulsion of significant volumes of blood (liters/min), but are limited by a need for a power supply, relatively large pumps, and the risk of hemolysis, thrombus formation, and infection. Temporary assist devices, intra-aortic balloons, and pacing devices have also been used.
In addition to cardiac transplant, which is highly invasive and limited by the ability of donor hearts, surgical approaches such as dynamic cardiomyoplastic or the Batista partial left ventriculectomy may also be used in severe cases.
Various devices have been developed using stents or conduits to modify blood pressure and flow within a given vessel, or between chambers of the heart. For example, U.S. Pat. No. 6,120,534 to Ruiz is directed to an endoluminal stent for regulating the flow of fluids through a body vessel or organ, for example for regulating blood flow through the pulmonary artery to treat congenital heart defects. The stent may include an expandable mesh having lobed or conical portions joined by a constricted region, which limits flow through the stent. The mesh may comprise longitudinal struts connected by transverse sinusoidal or serpentine connecting members. Ruiz is silent on the treatment of CHF or the reduction of left atrial pressure.
U.S. Pat. No. 6,468,303 to Amplatz et al. discloses a collapsible medical device and associated method for shunting selected organs and vessels. Amplatz discloses that the device may be suitable to shunt a septal defect of a patient's heart, for example, by creating a shunt in the atrial septum of a neonate with hypoplastic left heart syndrome (HLHS). Amplatz discloses that increasing mixing of pulmonary and systemic venous blood improves oxygen saturation. Amplatz discloses that depending on the hemodynamics, the shunting passage can later be closed by an occluding device. Amplatz is silent on the treatment of CHF or the reduction of left atrial pressure, as well as on means for regulating the rate of blood flow through the device.
U.S. Patent Publication No. 2005/0165344 to Dobak, III discloses an apparatus for treating heart failure that includes a conduit positioned in a hole in the atrial septum of the heart, to allow flow from the left atrium into the right atrium. Dobak discloses that the shunting of blood will reduce left atrial pressures, thereby preventing pulmonary edema and progressive left ventricular dysfunction, and reducing LVEDP. Dobak discloses that the conduit may include a self-expandable tube with retention struts, such as metallic arms that exert a slight force on the atrial septum on both sides and pinch or clamp the valve to the septum, and a one-way valve member, such as a tilting disk, bileaflet design, or a flap valve formed of fixed animal pericardial tissue. However, Dobak states that a valved design may not be optimal due to a risk of blood stasis and thrombus formation on the valve, and that valves can also damage blood components due to turbulent flow effects. Dobak does not provide any specific guidance on how to avoid such problems.
In view of the foregoing, it would be desirable to provide devices for reducing left atrial pressure, and apparatus for delivering such devices to the atrial septum of the heart.
The present invention overcomes the drawbacks of previously-known devices by providing apparatus for delivering a device for regulating blood pressure between a patient's left atrium and right atrium. The apparatus may include one or more latching legs, a release ring, a pull chord, a spring, and a catheter. The one or more latching legs may have a hook portion and may be configured to move from a first position, where the one or more latching legs extend radially outward, to a second position, where the one or more latching legs move radially inward to release the device. The pull chord may be configured to move the one or more latching legs from the first position to the second position. The catheter has a lumen and a center axis and the one or more latching legs and the pull chord may be at least partially disposed within the lumen. The hook portion of at least one of the one or more latching legs may hook outwardly away from the center axis to permit the latching legs to engage the device at the inner surface of the device.
At least one of the latching legs may include a ramp portion disposed proximal to the hook portion. The release ring may be coupled to the one or more latching legs and configured to contact an inner section of the ramp portion in the first position and to contact an outer section of the ramp portion in the second position. The pull chord may be coupled to the release ring such that actuation of the pull chord moves the release ring from the first position, where the one or more latching legs extend radially outward, to the second position, where the one or more latching legs move radially inward to release the device.
The apparatus may include a sheath and the catheter may be configured to be at least partially disposed within the sheath. The device may be configured to be disposed within the sheath in a contracted, delivery state. The one or more latching legs may be configured to move the device longitudinally forward and longitudinally backward through the sheath. Preferably, the apparatus is configured to deliver the device to an atrial septum of the patient.
In addition, the apparatus may include a handle coupled to the pull chord and disposed at a proximal end of the catheter, wherein the pull chord is actuated via the handle. A release ring base may be coupled to the release ring and the pull chord and the pull chord may move the release ring base to move the release ring from the first position the second position. A spring may be coupled to the release ring base, and the spring may be configured to bias the release ring towards the first position. In addition, the spring may be configured to limit travel of the release ring by reaching full compression. The apparatus also may include an annular member disposed proximal to release ring base and configured to maintain the spring between the release ring base and the annular member.
The one or more latching legs may include two latching legs that share a common ramp portion and a third latching leg having a separate ramp portion. The catheter may include a catheter end having an end lumen extending therethrough, and the one or more latching legs, the release ring, and the pull chord may be at least partially disposed within the end lumen.
In accordance with one aspect of the present invention, a method of delivering a device to a subject with heart pathology is provided. The method may include providing a delivery apparatus comprising one or more latching legs having a hook portion and a catheter having a lumen and a center axis, the one or more latching legs at least partially disposed within the lumen and the hook portion of the one or more latching legs configured to hook outwardly away from the center axis; coupling the hook portion to the device; positioning the device across a puncture through the fossa ovalis; and moving the one or more latching legs from a first position, where the one or more latching legs extend radially outward, to a second position, where the one or more latching legs move radially inward to decouple the hook portion from the device such that the device engages the atrial septum.
The method may include inserting the device in a sheath, partially retracting the sheath such that the device engages the left side of the atrial septum, and then fully retracting the sheath such that the device is partially disposed in the right atrium. The device may have first and second flared end regions and a neck region disposed therebetween, and optionally a tissue valve. The first flared end region may be disposed in, and engage, the atrial septum, and the second flared end region may be disposed in, and flank, the atrial septum.
The one or more latching legs may include a ramp portion disposed proximal to the hook portion and the delivery apparatus further comprises a release ring coupled to the one or more latching legs. In such an embodiment, moving the one or more latching legs further includes moving the release ring, via a pull chord, from the first position, where the release ring contacts an inner section of the ramp portion, to the second position, where the release ring contacts an outer section of the ramp portion.
Positioning the device may include positioning the device across the puncture through the fossa ovalis such that the neck region is positioned in the puncture. The method may include identifying the middle of the fossa ovalis of the atrial septum by pressing a needle against the fossa ovalis to partially tent the fossa ovalis, and puncturing the middle of the fossa ovalis with the needle. The puncture may be through the middle of the fossa ovalis and the device may be deployed away from the limbus, atrial wall, and the ridge between the inferior vena cava and coronary sinus.
In accordance with another aspect of the present invention, a method of delivering a device to a subject with heart pathology is provided. The method may include providing a delivery apparatus comprising one or more latching legs having a hook portion and a catheter having a lumen and a center axis, the one or more latching legs at least partially disposed within the lumen; coupling the hook portion to the device; positioning the device across a puncture through the fossa ovalis at a non-perpendicular angle between the center axis of the catheter and an outer wall of the atrial septum; and moving the one or more latching legs from a first position, where the one or more latching legs extend radially outward, to a second position, where the one or more latching legs move radially inward to decouple the hook portion from the device such that the device engages the atrial septum.
Embodiments of the present invention also provide hourglass-shaped devices for reducing left atrial pressure, and methods of making and using the same. As elaborated further herein, such reductions in left atrial pressure may increase cardiac output, relieve pulmonary congestion, and lower pulmonary artery pressure, among other benefits. The inventive devices are configured for implantation through the atrial septum, and particularly through the middle of the fossa ovalis, away from the surrounding limbus, inferior vena cava (IVC), and atrial wall. The devices are configured to provide one-way blood flow from the left atrium to the right atrium when the pressure in the left atrium exceeds the pressure in the right atrium, and thus decompress the left atrium. Such a lowering of left atrial pressure may offset abnormal hemodynamics associated with CHF, for example, to reduce congestion as well as the occurrence of acute cardiogenic pulmonary edema (ACPE), which is a severe manifestation of CHF in which fluid leaks from pulmonary capillaries into the interstitium and alveoli of the lung. In particular, lowering the left atrial pressure may improve the cardiac function by:
(1) Decreasing the overall pulmonary circulation pressure, thus decreasing the afterload on the heart,
(2) Increasing cardiac output by reducing left ventricular end systolic dimensions, and
(3) Reducing the left ventricular end-diastolic pressure (LVEDP) and pulmonary artery pressure (PAP), which in turn may enable the heart to work more efficiently and over time increase cardiac output. For example, the oxygen uptake of the myocardium may be reduced, creating a more efficient working point for the myocardium.
As described in further detail below, the devices provided herein comprise an hourglass or “diabolo” shaped stent encapsulated with a biocompatible material, and optionally secured (e.g., sutured) to a tissue valve. The stent, which may be formed of shape memory material, for example a shape memory metal such as NiTi, comprises a neck region disposed between two flared end regions. The tissue valve is coupled to a flared end region configured for implantation in the right atrium. Specifically, the device may be implanted by forming a puncture through the atrial septum, particularly through the fossa ovalis, and then percutaneously inserting the device therethrough such that the neck lodges in the puncture, the flared end to which the tissue valve is coupled engages the right side of the atrial septum, and the other flared end flanks the left side of the atrial septum (e.g., is spaced apart from and does not contact the left side of the atrial septum). Placement in the middle of the fossa ovalis is useful because the engagement of the right-side flared end with the atrial septum enhances the stability of the valve. The neck region and the flared end region for placement in the left atrium may each be covered with a biocompatible polymer, such as expanded polytetrafluoroethylene (ePTFE), polyurethane, DACRON (polyethylene terephthalate), silicone, polycarbonate urethane, or pericardial tissue from an equine, bovine, or porcine source, which is optionally treated so as to promote a limited amount of tissue ingrowth, e.g., of epithelial tissue or a neointima layer. The tissue valve is connected to the biocompatible polymer in the right-side flared end region, close to the neck region, and is preferably a tricuspid, bicuspid, or duckbill valve configured to allow blood to flow from the left atrium to the right atrium when the pressure in the left atrium exceeds that in the right atrium, but prevent flow from the right atrium to the left atrium. In preferred embodiments, the device is effective to maintain the pressure differential between the left atrium and right atrium to 15 mmHg or less.
Under one aspect of the present invention, a device for regulating blood pressure between a patient's left atrium and right atrium comprises an hourglass-shaped stent comprising a neck and first and second flared end regions, the neck disposed between the first and second end regions and configured to engage the fossa ovalis of the patient's atrial septum; and optionally a one-way tissue valve coupled to the first flared end region and configured to shunt blood from the left atrium to the right atrium when blood pressure in the left atrium exceeds blood pressure in the right atrium. In accordance with one aspect of the invention, moving portions of the valve are disposed in the right atrium, joined to but spaced apart from the neck region.
The hourglass-shaped stent may include a shape memory material (e.g., metal) coated with a biocompatible polymer from a portion of the first flared end region, through the neck region, and through the second flared end region, and the tissue valve may extend between the first flared end region and the biocompatible polymer. Providing the tissue valve in the side of the device to be implanted in the right atrium (that is, in the first flared end region) may inhibit thrombus formation and tissue ingrowth by providing that the tissue valve, as well as the region where the tissue valve is secured (e.g., sutured) to the biocompatible polymer, is continuously flushed with blood flowing through the right atrium. By comparison, if the tissue valve was instead secured (e.g., sutured) to the biocompatible polymer in the neck region, then the interface between the two would contact the tissue of the fossa ovalis, which potentially would encourage excessive tissue ingrowth, create leakages, and cause inflammation. Moreover, tissue ingrowth into the neck region would cause a step in the flow of blood in the narrowest part of the device, where flow is fastest, which would increase shear stresses and cause coagulation. Instead providing the tissue valve entirely within the right atrial side of the device inhibits contact between the tissue valve and the tissue of the atrial septum and fossa ovalis. Further, any tissue that ingrows into the valve will not substantially affect blood flow through the device, because the valve is located in a portion of the device having a significantly larger diameter than the neck region. Moreover, if the biocompatible tissue were instead to continue on the portions of the frame positioned over the tissue valve, it may create locations of blood stasis between the leaflets of the tissue valve and the biocompatible material. Having the valve entirely on the right atrial side and without biocompatible material on the overlying frame enables continuous flushing of the external sides of the tissue valve with blood circulating in the right atrium.
The biocompatible material preferably promotes limited (or inhibits excessive) tissue ingrowth into the valve, the tissue ingrowth including an endothelial layer or neointima layer inhibiting thrombogenicity of the device. The endothelial or neointima layer may grow to a thickness of 0.2 mm or less, so as to render the material inert and inhibit hyperplasia.
The hourglass-shaped stent may include a plurality of sinusoidal rings interconnected by longitudinally extending struts. In some embodiments, when the shunt is deployed across the patient's atrial septum, the first flared end region protrudes 5.5 to 7.5 mm into the right atrium. The second flared end region may protrude 2.5 to 7 mm into the left atrium. The neck may have a diameter of 4.5 to 5.5 mm. The first flared end region may have a diameter between 9 and 13 mm, and the second flared end region may have a diameter between 8 and 15 mm. The first and second flared end regions each may flare by about 50 to 120 degrees. For example, in one embodiment, the first flared end region flares by about 80 degrees, that is, the steepest part of the outer surface of the first flared end region is at an angle of approximately 40 degrees relative to a central longitudinal axis of the device. The second flared end region may flare by about 30-70 degrees, where the steepest part of the outer surface of the second flared end region may be at an angle of approximately 35 degrees relative to the central longitudinal axis of the device. The second flare may be have a tapered shape starting with a wider angle in the range of about 50-70 degrees and ending with a narrow angle in the range of about 30-40 degrees.
The inlet of the tissue valve may be about 1-3 mm from a narrowest portion of the neck region, and the outlet of the tissue valve may be about 5-8 mm from the narrowest portion of the neck region. The tissue valve may comprise a sheet of tissue having a flattened length of about 10-16 mm, and the sheet of tissue may be folded and sutured so as to define two or more leaflets each having a length of about 5-8 mm. For example, the tissue sheet may have a flattened length of no greater than 18 mm, for example, a length of 10-16 mm, or 12-14 mm, or 14-18 mm, and may be folded and sutured to define two or more leaflets each having a length of, for example, 9 mm or less, or 8 mm or less, or 7 mm or less, or 6 mm or less, or even 5 mm or less, e.g., 5-8 mm. The tissue sheet may have a flattened height no greater than 10 mm, for example, a height of 2-10 mm, or 4-10 mm, or 4-8 mm, or 6-8 mm, or 4-6 mm. The tissue sheet may have a flattened area of no greater than 150 square mm, for example, 60-150 square mm, or 80-120 square mm, or 100-140 square mm, or 60-100 square mm.
The hourglass-shaped stent may be configured to transition between a collapsed state suitable for percutaneous delivery and an expanded state when deployed across the patient's fossa ovalis. The stent may have an hourglass configuration in the expanded state. The hourglass configuration may be asymmetric. The stent may be configured for implantation through the middle of the fossa ovalis, away from the surrounding limbus, inferior vena cava, and atrial wall. The hourglass-shaped stent may be designed in such way that when collapsed into a sheath, the neck of the stent maintains a diameter smaller than the sheath inner diameter. The sheath may have a tapered tip with locally reduced diameter at its tip. The neck of the stent is configured to self-position itself within the sheath tip when the stent is partially deployed. Additionally, when the stent is partially deployed, a relatively high force is required to further advance the stent into the left atrium. Such additional force provides confirmation to the clinician that the stent is partially deployed, reduces the chance of total deployment in the left atrium, and reduces the risk that emboli will travel into the left atrium during full deployment.
The one-way tissue valve may have two or more leaflets, e.g., may have a tricuspid or bicuspid design. The one-way tissue valve may comprise pericardial tissue, which in one embodiment may consist primarily of the mesothelial and loose connective tissue layers, and substantially no dense fibrous layer. Note that the dimensions of the hourglass-shaped device may be significantly smaller than those of replacement aortic valves, which may for example have a diameter of 23 mm and require the use of larger, thicker valve leaflets to maintain the higher stresses generated by the combination of higher pressures and larger diameters. By comparison, the inventive device has much smaller dimensions, allowing the use of thinner tissue (e.g., about one third the thickness of tissue used in a replacement aortic valve), for example, pericardial tissue in which the external dense fibrous layer is delaminated and the mesothelial and loose connective tissue is retained.
Under another aspect of the present invention, a device for regulating blood pressure between a patient's left atrium and right atrium includes a stent comprising a neck region and first and second flared end regions, the neck region disposed between the first and second end regions and configured to engage the fossa ovalis of the patient's atrial septum; a biocompatible material disposed on the stent in the neck and the second flared end region and a portion of the first flared end region; and optionally a one-way tissue valve configured to shunt blood from the left atrium to the right atrium when blood pressure in the left atrium exceeds blood pressure in the right atrium, the valve having an outlet coupled to the first flared end region and an inlet coupled to an edge of the biocompatible material, the valve and the biocompatible material defining a continuous sheath that inhibits excessive tissue ingrowth into the valve and channels blood flow through the valve. In one embodiment, the edge of the biocompatible material is about 1-3 mm, e.g., 2 mm, from a narrowest portion of the neck region.
Under another aspect, a method of treating a subject with heart pathology comprises: providing a device having first and second flared end regions and a neck region disposed therebetween, and a tissue valve coupled to the first flared end region; deploying the device across a puncture through the subject's fossa ovalis such that the neck region is positioned in the puncture, the first flared end region is disposed in, and engages, the atrial septum, and the second flared end region is disposed in, and flanks, the atrial septum; and reducing left atrial pressure and left ventricular end diastolic pressure by shunting blood from the left atrium to the right atrium through the device when the left atrial pressure exceeds the right atrial pressure.
Subjects with a variety of heart pathologies may be treated with, and may benefit from, the inventive device. For example, subjects with myocardial infarction may be treated, for example by deploying the device during a period immediately following the myocardial infarction, e.g., within six months after the myocardial infarction, or within two weeks following the myocardial infarction. Other heart pathologies that may be treated include heart failure and pulmonary congestion. Reducing the left atrial pressure and left ventricular end diastolic pressure may provide a variety of benefits, including but not limited to increasing cardiac output; decreasing pulmonary congestion; decreasing pulmonary artery pressure; increasing ejection fraction; increasing fractional shortening; and decreasing left ventricle internal diameter in systole. Means may be provided for measuring such parameters.
Such methods may include identifying the middle of the fossa ovalis of the atrial septum by pressing a needle against the fossa ovalis to partially tent the fossa ovalis; and puncturing the middle of the fossa ovalis with the needle.
Under yet another aspect of the present invention, a method of making a device comprises: providing a tube of shape-memory metal; expanding the tube on a mandrel to define first and second flared end regions and a neck therebetween, and heating the expanded tube to set the shape; coating the neck and second flared end region with a biocompatible material; providing a valve of animal pericardial tissue having leaflets fixed in a normally closed position; and securing an inlet of the valve to the first flared end region and to the biocompatible polymer at the neck region. The tube may be laser cut and may include a plurality of sinusoidal rings connected by longitudinally extending struts, and the valve may be sutured to the struts and to the biocompatible material to form a passage for blood.
Embodiments of the present invention are directed to devices that reduce left atrial pressure, and thus may be useful in treating subjects suffering from congestive heart failure (CHF) or other disorders associated with elevated left atrial pressure. Specifically, the inventive device includes an hourglass or “diabolo” shaped stent, preferably formed of a shape memory metal, and, optionally, a biocompatible valve coupled thereto. The stent is configured to lodge securely in the atrial septum, preferably the fossa ovalis, and to allow blood flow from the left atrium to the right atrium, preferably through the fossa ovalis, and the valve may be used to allow one-way blood flow when blood pressure in the left atrium exceeds that on the right. Usefully, the inventive devices are configured so as to reduce blood pressure in the left atrium even when the pressure differential therebetween is relatively low; to provide a smooth flow path with a large opening, thus inhibiting turbulence and high shear stresses that would otherwise promote thrombus formation; to seal securely with rapid valve closure when the left and right atrial pressures equalize or the right atrial pressure exceeds left atrial pressure; and to have a relatively small implantation footprint so as to inhibit tissue overgrowth and inflammatory response.
First, a preferred embodiment of the inventive hourglass-shaped device will be described, and then methods of making, implanting, and using the same will be described. Then, the hemodynamic flow characteristics of some illustrative devices will be described, as well as a method for using an hourglass-shaped device to noninvasively determine left atrial pressure based on images of blood flowing through the implanted device. Some alternative embodiments will then be described. An Example will be provided that describes a study performed on several animals into which an exemplary device was implanted, as compared to a group of control animals. Apparatus for delivering the devices of the present invention also will be described.
Hourglass-shaped stent 110 is preferably formed of a shape memory metal, e.g., NITINOL, or any other suitable material known in the art. Stent 110 includes a plurality of sinusoidal rings 112-116 interconnected by longitudinally extending struts 111. Rings 112-116 and struts 111 may be of unitary construction, that is, entire stent 110 may be laser cut from a tube of shape memory metal. As can be seen in
An inlet end of tissue valve 130 is coupled to stent 110 in first flared end region 102. In the illustrated embodiment, tissue valve 130 is a tricuspid valve that includes first, second, and third leaflets 131 defining valve opening 132. Other embodiments, illustrated further below, may include a bicuspid or duckbill valve, or other suitable valve construction. However, it is believed that tricuspid valves may provide enhanced leaflet coaptation as compared to other valve types, such that even if the tissue valve stiffens as a result of tissue ingrowth following implantation, there may still be sufficient leaflet material to provide coaptation with the other leaflets and close the valve. Preferably, tissue valve 130 opens at a pressure of less than 1 mm Hg, closes at a pressure gradient of between 0-0.5 mm Hg, and remains closed at relatively high back pressures, for example at back pressures of at least 40 mm Hg. Tissue valve 130 may be formed using any natural or synthetic biocompatible material, including but not limited to pericardial tissue, e.g., bovine, equine, or porcine tissue, or a suitable polymer. Pericardial tissue, and in particular bovine pericardial tissue, is preferred because of its strength and durability. The pericardial tissue may be thinned to enhance compliance, for example as described in greater detail below, and may be fixed using any suitable method, for example, using glutaraldehyde or other biocompatible fixative.
As shown in
To achieve such flow effects, as well as reduce complexity of device fabrication, tissue valve 130 preferably is a tricuspid valve, as is illustrated in
As noted above, hourglass-shaped device 100 preferably is configured for implantation through the fossa ovalis of the atrial septum, particularly through the middle of the fossa ovalis. As known to those skilled in the art, the fossa ovalis is a thinned portion of the atrial septum caused during fetal development of the heart, which appears as an indent in the right side of the atrial septum and is surrounded by a thicker portion of the atrial septum. While the atrial septum itself may be several millimeters thick and muscular, the fossa ovalis may be only approximately one millimeter thick, and is formed primarily of fibrous tissue. Advantageously, because the fossa ovalis comprises predominantly fibrous tissue, that region of the atrial septum is not expected to undergo significant tension or contraction during the cardiac cycle, and thus should not impose significant radial stresses on stent 110 that could lead to stress-induce cracking. In addition, the composition of the fossa ovalis as primarily fibrous tissue is expected to avoid excessive endothelialization after implantation.
In some embodiments of the present invention, hourglass-shaped device 100 is asymmetrically shaped to take advantage of the natural features of atrial septum 210 near the fossa ovalis, and to provide suitable flow characteristics.
In accordance with one aspect of the invention, device 100 preferably is configured so as to avoid imposing significant mechanical forces on atrial septum 210 or atria 202, 204, allowing the septum to naturally deform as the heart beats. For example, muscular areas of septum 210 may change by over 20% between systole and diastole. It is believed that any significant mechanical constraints on the motion of atrial septum 210 in such areas would lead to the development of relatively large forces acting on the septum and/or on atrial tissue that contacts device 100, which potentially would otherwise cause the tissue to have an inflammatory response and hyperplasia, and possibly cause device 100 to eventually lose patency. However, by configuring device 100 so that neck region may be implanted entirely or predominantly in the fibrous tissue of the fossa ovalis 212, the hourglass shape of device 100 is expected to be sufficiently stable so as to be retained in the septum, while reducing mechanical loads on the surrounding atrial septum tissue 210. As noted elsewhere herein, tissue ingrowth from atrial septum 210 in regions 230 may further enhance binding of device 100 to the septum.
Also, for example, as illustrated in
In some embodiments, the length of first flared end region 102 also may be selected to protrude into the right atrium by a distance R between the narrowest portion of neck region 104 and the end of first flared region 102 may be approximately 5.0 to 9.0 mm, for example about 5.5 to about 7.5 mm, or about 6 to about 7 mm, so as not to significantly protrude above the limbus of fossa ovalis 212. Second flared end region 106 preferably does not significantly engage the left side of atrial septum 210, and distance L may be between 2.0 and 8.0 mm, for example about 4 to 7 mm, or about 6.0 mm. It is believed that configuring first and second flared end regions 102, 106 so as to extend by as short a distance as possible into the right and left atria, respectively, while still maintaining satisfactory flow characteristics and stabilization in atrial septum 210, may reduce blockage of flow from the inferior vena cava (IVC) in the right atrium and from the pulmonary veins in the left atrium. In one illustrative embodiment, distance R is about 6.5 mm and distance L is about 6.0 mm. In some embodiments, the overall dimensions of device 100 may be 8-20 mm long (L+R, in
The diameters of the first and second flared end regions further may be selected to stabilize device 100 in the puncture through atrial septum 210, e.g., in the puncture through fossa ovalis 212. For example, first flared end region 102 may have a diameter of 8-15 mm at its widest point, e.g., about 10-13 mm or about 11.4 mm; and second flared end region 106 may have a diameter of 10-20 mm at its widest point, e.g., about 13-16 mm or about 14.4 mm. The largest diameter of first flared end region 102 may be selected so as to avoid mechanically loading the limbus of the fossa ovalis 212, which might otherwise cause inflammation. The largest diameter of second flared end region 106 may be selected so as to provide a sufficient angle between first and second flared end regions 102, 106 to stabilize device 100 in the atrial septum, while limiting the extent to which second flared end region 106 protrudes into the left atrium (e.g., inhibiting interference with flow from the pulmonary veins), and providing sufficient blood flow from the left atrium through neck region 104. In one embodiment, the angle between the first and second flared end regions is about 70-140 degrees, e.g., about 90 to 130 degrees, e.g., about 100 degrees. Such an angle may stabilize device 100 across the fossa ovalis, while inhibiting excessive contact between the device and the atrial septum. Such excessive contact might cause inflammation because of the expansion and contraction of the atrial septum during the cardiac cycle, particularly between diastole and systole. In one embodiment, the first flared end region subtends an angle of approximately 80 degrees, that is, the steepest part of the outer surface of the first flared end region is at an angle of approximately 40 degrees relative to a central longitudinal axis of the device. The second flared end region may flare by about 30-70 degrees, where the steepest part of the outer surface of the second flared end region may be at an angle of approximately 35 degrees relative to the central longitudinal axis of the device. The second flare may be have a tapered shape starting with a wider angle in the range of about 50-70 degrees and end with a narrow angle in the range of about 30-40 degrees.
Tissue valve 130 is preferably configured such that when closed, leaflets 131 define approximately straight lines resulting from tension exerted by stent 110 across valve opening 132, as illustrated in
When device 100 is implanted across the atrial septum, as illustrated in
In the region of contact between device 100 and atrial septum 210, preferably there is limited tissue growth. The connective tissue of atrial septum 210 is non-living material, so substantially no nourishing of cells occurs between the septum and device 100. However, local stagnation in flow may lead to limited cell accumulation and tissue growth where device 100 contacts atrial septum 210, for example in regions designated 230 in
A method 300 of making device 100 illustrated in
First, a tube of shape-memory material, e.g., a shape-memory metal such as nickel titanium (NiTi), also known as NITINOL, is provided (step 301 of
Then, the tube is laser-cut to define a plurality of sinusoidal rings connected by longitudinally extending struts (step 302). For example, struts 111 and sinusoidal rings 112-116 illustrated in
Referring again to
As shown in
The biocompatible material facilitates funneling of blood from the left atrium to the right atrium by facilitating the formation of a pressure gradient across tissue valve 130, as well as providing a substantially smooth hemodynamic profile on both the inner and outer surfaces of device 100. Advantageously, this configuration is expected to inhibit the formation of eddy currents that otherwise may cause emboli to form, and facilitates smooth attachment of the device to the atrial septum, e.g., fossa ovalis. Biocompatible material 120 preferably is configured so as to direct blood flow from the left atrium, through neck region 104 and toward tissue valve leaflets 131. Biocompatible material 120 preferably also is configured so as to inhibit tissue growth from atrial septum 210 and surrounding tissue into device 100 and particularly toward tissue valve leaflets 131. In some embodiments, the biocompatible material 120 has a porosity that is preselected to allow limited cell growth on its surface; the cells that grow on such a surface preferably are endothelial cells that are exposed to blood and inhibit blood from coagulating on the biocompatible material. After such cells grow on the biocompatible material 120, the material preferably is substantially inert and thus not rejected by the body. Optionally, the biocompatible material may be impregnated with a second material that facilitates tissue ingrowth, e.g., carbon. Such impregnation may be performed before or after applying the biocompatible material to the stent.
Then, as shown in
The tissue may have a thickness, for example, of between 0.050 mm and 0.50 mm, for example, about 0.10 mm and 0.20 mm. Typically, harvested bovine pericardial tissue has a thickness between about 0.3 mm and 0.5 mm, which as is known in the art is a suitable thickness for high-stress applications such as construction of aortic valves. However, for use in the device of the present invention, it may be preferable to thin the pericardial tissue. For example, the stresses to which the valve leaflets are exposed in a device constructed in accordance with the present invention may be a small fraction (e.g., 1/25th) of the stresses in an aortic valve application, because of the relatively large surface area of the leaflets and the relatively low pressure gradients across the device. For this reason, thinned pericardial tissue may be used, enabling construction of a more compliant valve that may be readily fixed in a normally closed position but that opens under relatively low pressure gradients. Additionally, the use of thinner leaflets is expected to permit the overall profile of the device to be reduced in when the device is compressed to the contracted delivery state, thereby enabling its use in a wider range of patients.
For example, harvested pericardial tissue typically includes three layers: the smooth and thin mesothelial layer, the inner loose connective tissue, and the outer dense fibrous tissue. The pericardial tissue may be thinned by delaminating and removing the dense fibrous tissue, and using a sheet of the remaining mesothelial and loose connective layers, which may have a thickness of 0.10 mm to 0.20 mm, to construct the tissue valve. The dense fibrous tissue may be mechanically removed, for example using a dermatome, grabbing tool, or by hand, and any remaining fibers trimmed.
The animal pericardial tissue then may be three-dimensionally shaped on a mandrel to define a tissue valve having valve leaflets that are normally in a closed position, and then fixed in that position using glutaraldehyde or other suitable substance (step 306). Excess glutaraldehyde may be removed using an anticalcification treatment, for example to inhibit the formation of calcium deposits on the tissue valve.
The outlet or upper (wider) portion of the tissue valve then may be secured, e.g., sutured, to the first flared end region, and the inlet or lower (narrower) portion of the tissue valve secured, e.g., sutured to the biocompatible polymer at the neck region (step 307). For example, as illustrated in
A method 400 of using device 100 illustrated in
First, an hourglass-shaped device having a plurality of sinusoidal rings connected by longitudinally extending struts that define first and second flared end regions and a neck disposed therebetween, as well as a tissue valve coupled to the first flared end region, is provided (step 401). Such a device may be provided, for example, using method 300 described above with respect to
Then, the device is collapsed radially to a contracted delivery state, and loaded into a loading tube (step 402). For example, as illustrated in
Referring again to
Referring again to
The device then is advanced out of the loading tube and into the sheath using a pusher, and then partially advanced out of the sheath, such that the second flared end of the device protrudes out of the sheath and into the left atrium, and expands to its deployed state (step 407). For example, as illustrated in
The sheath then is retracted, causing the second flared end region to flank the left side of the atrial septum and the neck of the device to lodge in the puncture through the fossa ovalis, and allowing expansion of the first flared end of the device into the right atrium (step 408, see also
The performance characteristics of device 100 were characterized using computational fluid dynamic modeling.
The performance of device 100 was also characterized using hemodynamic testing.
Additionally, device 100 was subjected to an accelerated wear and fatigue test for up to 100 million cycles to simulate and predict fatigue durability, and was observed to perform satisfactorily.
The devices and methods described herein may be used to regulate left atrial pressures in patients having a variety of disorders, including congestive heart failure (CHF), as well as other disorders such as patent foramen ovale (PFO), or atrial septal defect (ASD). The devices and methods also may be used to reduce symptoms and complications associated with such disorders, including myocardial infarction. It is believed that patients receiving the device may benefit from better exercise tolerance, less incidence of hospitalization due to acute episodes of heart failure, and reduced mortality rates.
The devices and methods described herein further may be used to non-invasively determine the pressure in the left atrium, and thus to assess the efficacy of the device and/or of any medications being administered to the patient. Specifically, with respect to
Some alternative embodiments of device 100 described above with respect to
Duckbill tissue valve 830 is coupled to stent 110 in first flared end region 102. Preferably, tissue valve 830 opens at a pressure of less than 1 mmHg, closes at a pressure gradient of 0 mmHg, and remains closed at relatively high back pressures, for example at back pressures of at least 40 mmHg. Like tissue valve 130, tissue valve 830 may be formed using any natural or synthetic biocompatible material, including but not limited to pericardial tissue, e.g., thinned and fixed bovine, equine, or porcine pericardial tissue. As shown in
Referring now to
Duckbill tissue valve 930 is coupled to stent 910 in first flared end region 902. Specifically, the outlet of tissue valve 930 is coupled, e.g., sutured, to first and second longitudinally extending struts 911′, 911″ in the region extending between the first (uppermost) sinusoidal ring 912 and the distal ends of struts 911′, 911″. The inlet end of tissue valve 930 also is coupled, e.g., sutured, to the upper edge of biocompatible material 920 at or near first (uppermost) sinusoidal ring 912, so as to provide a smooth profile. Device 900 is preferably configured so as to provide flow characteristics similar to those described above for device 100.
An exemplary device 800 such as described above with respect to
Chronic heart failure was induced in animals C1-C4 and V1-V4, who were less than 1 year of age and weighed between 70 and 120 pounds, by first anesthetizing the animals via a venous catheter positioned in a peripheral vessel, i.e., the ear. The animals were given an opiate or synthetic opiate (e.g., morphine or butorphanol) intravenously at 0.25 to 0.5 mg/kg, as well as telazol at 0.3 mg/kg, through the venous catheter, and anesthetized by intravenous etomidate. Anesthesia was maintained with 1.5% isoflurane delivered in 100% O2, via a tracheal tube. The animals were placed on a fluoroscope table in left lateral recumbence, and a gastric tube (about 7 F) was inserted into the rumen to serve as a vent.
An introducer was then positioned within the carotid artery via cut down and modified Seldinger technique. A 6 F or 7 F Judkins left 4.5 catheter was advanced through the introducer into the left circumflex coronary artery (LCxA) under fluoroscopic guidance, and about 60,000 polystyrene microspheres of about 90 μm diameter were injected into the LCxA to induce embolization to induce myocardial infarction followed by chronic heart failure. The arterial and skin incisions then were closed, and the animals were administered about 500 mg of cephalexein p.o. bid for two days, as well as a synthetic opiate pm, specifically buprenorphine administered intramuscularly at about 0.03 to 0.05 mg/kg, once during recovery and following the anesthesia. Animals observed to have arrhythmia following or during the microsphere injection were also administered lidocaine following embolization, at about 2 to 4 mg/kg via intravenous bolus, followed by constant infusion at about 20 to 80 μf/kf/minute.
This procedure was repeated one week following the first procedure in animals V1-V4 and C1-C4. This model of induced chronic heart failure has about a 100% fatality rate at 12 weeks, and as discussed below each of the control animals died before the end of the 12 week study. The procedure was performed a single time in animal S1, and as discussed below this animal survived the 12 week study but deteriorated over the course of the study.
Device 800 was implanted into four animals V1-V4. Fluid filled catheters were implanted into animals V1-V4 and C1-C4, approximately seven days after the second embolization procedure. Fluid filled catheters were not implanted into animal S1. The implanted device 800 had an overall length of 15 mm (7 mm on the left atrial side and 8 mm on the right atrial side), a diameter on the left atrial side of 14 mm, a diameter on the right atrial side of 13 mm, an inside neck diameter of 5.3 mm, and an angle between the left and right atrial sides of the device of 70 degrees. The fluid filled catheters were implanted in the inferior vena cava (IVC), superior vena cava (SVC), pulmonary artery, and left atrium through a right mini-thoracotomy under anesthesia, and were configured to measure oxygen saturations and pressures in the IVC, pulmonary artery, right atrium, and left atrium. After implantation and throughout the study, the animals were each treated daily with aspirin, plavix, and clopidogrel. Their heart rate was periodically monitored.
Two-dimensional M-mode echocardiograms of the left ventricle were periodically obtained to document the ejection fraction (EF), as well as the shortening fraction, calculated as 100(EDD−ESD)/EDD, where EDD is the end-diastolic dimension (diameter across ventricle at the end of diastole) and ESD is the end-systolic dimension (diameter across ventricle at the end of systole). Echocardiographic studies of the animals were performed while they were either conscious or under light chemical restraint with butorphanol, and manually restrained in the right or left decubitis position, using an ultrasound system with a 3.5 to 5.0 mHz transducer (Megas ES, model 7038 echocardiography unit). The echocardiograms were recorded for subsequent analysis. The left ventricle fractional area shortening (FAS), a measure of left ventricle systolic function, was measured from the short axis view at the level of the papillary muscles. Measurements of left ventricle dimensions, thickness of the posterior wall, and intraventricular septum were obtained and used as an index of left ventricle remodeling. The major and minor axes of the left ventricle were measured and used to estimate left ventricle end-diastolic circumferential wall stress.
The clinical conditions of the animals were evaluated by comparing various parameters over a twelve-week period, including left atrial pressure, right atrial pressure, pulmonary artery pressure, and ejection fraction (EF). Parameters such as left and right atrial pressures, left and right ventricular dimensions, and left and right ventricular function were obtained based on the collected data. Data obtained during the study are discussed further below with respect to
During the course of the study, all four of the control animals C1-C4 were observed to suffer from high pulmonary artery pressure, high right atrial pressure, and low ejection fraction, and were immobile. All four control animals died during the trial, C3 at week 1, C4 at week 3, C1 at week 6, and C2 at week 9. Animal S1 survived but deteriorated over the course of the study.
By comparison, all of the animals V1-V4 into which the device had been implanted were observed to have dramatically improved hemodynamic conditions over the course of the study, and appeared healthy and energetic without signs of congestion by the end of the study. As discussed below with reference to
Three of the four implanted animals, V1, V3, and V4 survived the twelve week study. One of the implanted animals, V2, died at week 10 of a non-heart failure cause. Specifically, arrhythmia was diagnosed as the cause of death; the animal was observed to have arrhythmia at baseline, and had been defibrillated before implantation Throughout the study, this animal was observed to have good hemodynamic data. At the end of the study, the surviving implant animals were observed to respond normally to doses of dobutamine, indicating significant improvement in the condition of their heart failure.
Upon explantation at the end of the study, three of the four implanted devices were observed to be completely patent and functional. For example,
Tables 2 through 15 present raw data obtained from the control animals C1-C4 and S1 and the implanted animals V1-V4, while awake, over the course of the 12 week study, including baseline immediately before implantation (Day 0, during which the animals were sedated). The mean values for control animals C1-C4 and S1 (M.C.) and the mean values for the implanted animals V1-V4 (M.V.), with standard deviations, are also presented in the tables. Missing data indicates either the death of the animal or omission to obtain data. Data for animal C3 is not shown because the animal died in the first week of the study. Data was not collected for any animal in week 7 of the study. As noted above, animal S1 was not implanted with pressure and saturation flow monitors, so no data is shown for that animal for certain measurements.
Table 2 presents the study's results pertaining to right atrial pressure (RAP, mmHg). As can be seen from Table 2, the average RAP for the control animals (C1-C4) increased significantly over the course of the study. For example, animal C1 experienced an RAP increase to about 330% of baseline before death, C2 to about 110% of baseline before death, and C4 to about 340% of baseline before death. The increase was relatively steady during this period. By contrast, the RAP for the implanted animals (V1-V4) started at a similar value to that of the control animals, at an average of 6±2 mmHg at baseline, but did not significantly vary over the course of the study. Instead, the average RAP of the implanted animals remained within about 1-2 mmHg of the baseline value for the entire study (between a high of 7±1 and a low of 5±1). Thus, the inventive device may inhibit increases in the right atrial pressure in subjects suffering from heart failure, and indeed may maintain the right atrial pressure at or near a baseline value. This is particularly noteworthy because, as described elsewhere herein, the device may offload a relatively large volume of blood from the left atrium to the right atrium; however the relatively high compliance of the right atrium inhibits such offloading from significantly increasing RAP.
Table 3 presents the study's results pertaining to left atrial pressure (LAP, mmHg). As can be seen from Table 3, the average LAP of the control animals started at a similar value at baseline as that of the implanted animals, 14±1 mmHg for the former and 15±2 mmHg for the latter. However, the LAP of the control animals increased significantly over the course of the study. For example, animal C1 had a baseline LAP of 10.6 mmHg, and an LAP of 27.3 mmHg at week 9 just before death, about 250% of baseline. The LAP increases of the other control animals were smaller, but still significantly larger than that of the implanted animals. Indeed, in each case the LAP of the implanted animals actually decreased immediately following implantation. For example, the LAP for animal V1 decreased from 15.7 mmHg at baseline to 11.4 mmHg one week following implantation, about 73% of baseline. The average LAP for the implanted animals decreased from 15±2 at baseline to a low of 11±0 at week one, and then gradually increased to about 13±1 at week six (about 87% of baseline), where it remained for the remainder of the study.
Table 4 further elaborates the results presented in Table 3, and presents the calculated change in LAP (ALAP, %). As can be seen in Table 4, control animals C2 and C4 each died after their LAP increased by about 44%, while control animal C1 died after its LAP increased by about 158%. By comparison, implanted animals V1, V2, and V3 each experienced significant decreases in LAP immediately following implantation, e.g., by about −27%, −41%, and −15% relative to baseline. The LAP for animal V4 remained near baseline following implantation. The LAP for animal V1 slowly increased back to baseline over the course of the study; the LAP for animal V2 remained significantly below baseline before its death but increased somewhat; the LAP for animal V3 also remained below baseline throughout the study but increased somewhat; and the LAP for animal V4 fluctuated somewhat above baseline but remained within about 18% of baseline. Thus, it can be seen that the inventive device may inhibit increases in the left atrial pressure in patients suffering from heart failure. Indeed, the device may actually decrease the left atrial pressure below baseline in patients suffering from heart failure for a time period immediately following implantation, in some embodiments to a level about 20% below baseline. The left atrial pressure subsequently may gradually increase back towards a baseline level over a time period of weeks or months, as the heart remodels and improves in efficiency. It is important to note that the control animals died from pulmonary edema, which correlates with LAPs that exceed the “danger zone” of 25 mmHg or more at which edema occurs.
Table 5 presents the study's results pertaining to pulmonary artery pressure (PAP, mmHg). As can be seen in Table 5, the control animals experienced significant increases in PAP before death, e.g., about 230% of baseline for animal C1, 217% of baseline for animal C2, and 180% of baseline for animal C4. The PAP for the implanted animals also increased over the course of the study, but in most cases by significantly less than that of the control animals, e.g., to about 133% of baseline for animal V1, about 161% of baseline for animal V2, about 156% of baseline for animal V3, and about 169% for animal V4. The inventive device thus may inhibit increases in pulmonary artery pressure in subjects suffering from heart failure, relative to what they may otherwise have experienced during heart failure.
Table 6 presents the study's results pertaining to heart rates (HR, beats per minute). During each week of the study, except for week one, it can be seen that the heart rates of the control animals (C1-C4 and S1) were higher than those of the implanted animals. Thus the inventive device may reduce heart rate in subjects suffering from heart failure. Put another way, the inventive device provides may enhance the efficiency of the pulmonary system and therefore reduce the frequency with which the heart must beat to satisfy the body's oxygen demands.
Table 7 presents the study's results relating to oxygen saturation in the vena cava (VC_SO2, %). The control animals and the implanted animals had similar VC_SO2 levels throughout the course of the study, although for both groups the levels were lower than at baseline. It is expected that oxygen saturation in the vena cava is relatively low, because the vessel carries deoxygenated blood from the body to the heart.
Table 8 presents the study's results relating to oxygen saturation in the pulmonary artery (PA_SO2, %). The PA_SO2 values for the implanted animals are somewhat higher than those for the control animals (e.g., between about 5-10% higher), indicating that device 100 was patent and transferring blood from the left atrium to the right atrium. It is expected that oxygen saturation in the pulmonary artery is relatively low, because the vessel carries deoxygenated blood from the heart to the lungs.
Table 9 presents the oxygen saturation in the left atrium (LA_SO2, %). The LA_SO2 values for the implanted animals are similar to those for the control animals. Animals with LA_SO2 values of less than 94% are considered to have low cardiac output.
Table 10 presents the study's results pertaining to the left ventricle internal diameter in diastole (LVIDd, cm), which also may be referred to in the art as left ventricular end-diastolic dimension (LVEDD or LVDD). It may be seen that the LVIDd for the control (C1-C4 and S1) and implanted (V1-V4) animals were relatively similar, and does not significantly vary during weeks 1-12 of the study. This may be attributed to the relatively low pressures during implantation. It may be expected that when the device 100 is implanted in a subject with high LAP, the LVIDd will decrease after implantation as a result of the significant reduction in LAP.
Table 11 presents the study's results pertaining to the left ventricle internal diameter in systole (LVIDs, cm), which also may be referred to in the art as left ventricular end-systolic dimension (LVESD or LVSD). While the LVIDd discussed above with respect to Table 10 was similar for both groups of animals, it may be seen here that for the control animals, the LVIDs increased from baseline in week one (e.g., from an average 3.5±0.2 at baseline to 4.2±0.3 at week one), and then increased further and/or remained elevate. By comparison, the LVIDs for the implanted animals increased slightly from baseline in week one (e.g., from an average 4.0±0.2 at baseline to 4.2±0.4 at week one), but then decreased relatively steadily over the course of the study (e.g., to 3.5±0.4 at week twelve). This decrease reflects the remodeling of the left ventricle over time that results from offloading blood flow from the left atrium back to the right atrium through the inventive device.
Table 12 elaborates on the results of Table 11, and presents the changes in the left ventricle internal diameter in systole (ΔLVIDs, %). As can be seen in Table 12, the control animals experienced an average increase in LVIDs of about 20-29% over the course of the study, while the implanted animals experienced an average decrease in LVIDs of about 0-9%. Thus, the inventive device may inhibit increases in the internal diameter of the left ventricle in subjects suffering from heart disease, and indeed may reduce the internal diameter of the left ventricle in subjects suffering from heart disease, in some embodiments by up to 10%.
Table 13 presents the study's results pertaining to ejection fraction (EF, %). The EF of the control animals may be seen to decline significantly over the course of the study, while the EF of the implanted animals increases significantly over the course of the study. For example, it may be seen that for the control animals, C1 experienced a decline in EF to about 45% of baseline; C2 to about 28% of baseline; C4 to about 47% of baseline; and S1 to about 41% of baseline. By comparison, for the implanted animals, V1 experienced an increase in EF to about 169% of baseline; V2 also to about 169% of baseline; V3 to about 129% of baseline; and V4 to about 127% of baseline. The inventive device thus may not only inhibit decreases in EF of subjects suffering from heart failure, but indeed may increase the EF of such subjects significantly, for example by 25-50%, or even 25-70% or more.
Table 14 elaborates on the results presented in Table 14, and presents the change in ejection fraction. As can be seen in Table 14, the EF of each of the control animals decreased significantly relative to baseline, e.g., by up to 72% for animal C2, while the EF for each of the implanted animals increased significantly.
As noted above with respect to Table 10, the left ventricle internal diameter in diastole (LVIDd) did not significantly change for the implanted animals over the course of the study. Absent such a decrease in the LVIDd, an increase in the EF may be interpreted as an increase in cardiac output. The inventive device thus may not only inhibit decreases in cardiac output of subjects suffering from heart failure, but indeed may increase the cardiac output of such subjects significantly.
Table 15 presents the study's results pertaining to fractional shortening (FS, %). Similar to ejection fraction discussed above with respect to Tables 13-14, the FS of each of the control animals may be seen in Table 15 to decline significantly over the course of the study. For example, animal C1 experienced a decline in FS to about 47% of baseline before death; animal C2 to about 24% of baseline; animal C4 to about 46% of baseline; and animal S1 to about 39% of baseline. In contrast, the FS of each of the implanted animals increased significantly over the course of the study. For example, animal V1 experienced an increase in FS to about 183% of baseline; animal V2 to about 166% of baseline; animal V3 to about 132% of baseline; and animal V4 to about 127% of baseline. Thus, the inventive device not only inhibits decreases in fractional shortening for subjects suffering from heart failure, but also may increase fractional shortening significantly, e.g., by about 25-85% of baseline.
As the foregoing results illustrate, devices constructed and implanted according to the present invention may provide for significantly improved mortality rates in subjects suffering from heart failure. In particular, the devices may significantly enhance ejection fraction, fractional shortening, and/or cardiac output in subjects who would otherwise have significantly diminished cardiac function as a result of excessive left atrial and left ventricular pressures. For example, subjects may be classified under the New York Heart Association (NYHA) classification system as having Class II (Mild) heart failure, who have slight limitation of physical activity and are comfortable at rest, but for whom ordinary physical activity results in fatigue, palpitation, or dyspnea; Class III (Moderate) heart failure, who have marked limitation of physical activity, may be comfortable at rest, and may experience fatigue, palpitation, or dyspnea if they engage in less than normal activity; or as having Class IV (Severe) heart failure, who are unable to carry out any physical activity without discomfort, exhibit symptoms of cardiac insufficiency at rest, and have increased discomfort if they undertake any physical activity. The present devices may significantly increase the cardiac output of such class III or class IV subjects, particularly those with low ejection fraction, enabling them to engage in significantly more physical activity than they otherwise could. The present devices further may decrease pulmonary artery pressure in subjects with left heart failure, and additionally may reduce or inhibit pulmonary congestion in patients with pulmonary congestion resulting from such heart failure, for example by inhibiting episodes of acute pulmonary edema. Indeed, as the above-described Example illustrates, the inventive device may reduce LAP and PAP significantly relative to what those pressures would otherwise be; such pressure reductions may not only provide immediate relief from acute symptoms, but further may facilitate cardiac remodeling over the weeks following implant and thus provide for enhanced cardiac function. The devices may in some embodiments include means for measuring the various parameters of interest, e.g., means such as discussed above with respect to the animal trials.
Delivery System
Referring to
Referring now to
Release ring 1246 is coupled to latching legs 1212, 1214, and 1216. For example, latching legs 1212, 1214, and 1216 may be partially disposed within release ring 1246 as illustrated in
Annular member 1248 may be partially disposed in the proximal end of catheter end 1224 and configured to couple catheter end 1224 to catheter 1204 via a suitable coupling mechanism, e.g., teeth 1250, ribs. Annular member 1248 includes lumen 1252 sized to accept pull chord 1254 therethrough.
Pull chord 1254 is coupled to release ring 1246 and actuation of pull chord 1254 moves release ring 1246 from the first position shown in
Pull chord 1254 may be coupled to release ring 1246 via release ring base 1256. In this embodiment, release ring base 1256 is directly coupled to release ring 1246 and pull chord 1254 such that actuation of pull chord 1254 moves release ring base 1256 to move release ring 1246 from the first position the second position, and vice versa.
Spring 1258 may be coupled to the proximal surface of release ring base 1256 and the distal surface of annular member 1248 such that release ring base 1256 and annular member 1248 maintain spring 1258 therebetween. Spring 1258 is configured to bias release ring 1246 towards a particular position such as towards the first position as shown in
Exemplary method 1600 of delivering device 100 illustrated in
First, a device and apparatus for delivering the device are provided (step 1601). The device may be an hourglass-shaped device having a plurality of sinusoidal rings connected by longitudinally extending struts that define first and second flared end regions and a neck disposed therebetween, as well as an optional tissue valve coupled to the first flared end region. Such a device may be provided, for example, using method 300 described above with respect to
Then, the device is collapsed radially to a contracted, delivery state and coupled to the delivery apparatus (step 1602). For example, as illustrated in
In
Referring to
Referring back to
Referring again to
Distal end 1202 of apparatus 1200, with device 100 coupled thereto in a contracted, delivery state, then is advanced into the sheath (step 1606). For example, the delivery system may be flushed, e.g., via fluid connected to fluid tube 1730, and then loading cartridge 1714 may be coupled to sheath 1726, e.g., via port 1728, as illustrated in
Then, under fluoroscopic or echocardiographic visualization, sheath 1726 may be repositioned such that the distal tip of sheath 1726 is disposed a predetermined distance, e.g., approximately 1-2 cm, distal to the fossa ovalis towards the left atrium. Next, device 100 and apparatus 1200 are advanced distally such that the device is partially advanced out of the sheath so the second flared end of the device protrudes out of the sheath and into the left atrium, and expands to its deployed state (step 1607). For example, device 100 and apparatus 1200 may be advanced distally until the handle at proximal end 1206 contacts knob 1722 as shown in
As another example, the angle θ″ may be substantially less than 90 degrees as shown in
An hourglass shape may aid in non-perpendicular deployment because the flared ends of the device engage the atrial septum, even when positioned at an angle relative to the central axis of the puncture through the atrial septum.
Next, under fluoroscopic or echocardiographic visualization, it is verified that the second flared end of the device protrudes from sheath 1726 and then knob 1722 is used to lock the delivery system in place. Sheath 1726 is pulled proximally to perform “back tenting,” causing the second flared end region of device 100 to engage the left side of the atrial septum AS as shown in
Using fluoroscopic or echocardiographic visualization, the clinician next verifies that the device is positioned across the fossa ovalis. The clinician then reduces the pulling force of the sheath and allows the fossa ovalis to straighten. Then, while holding sheath 1726 in place, knob 1722 is released and the components at distal end 1202 of apparatus 1200 are moved from an engaged position to a disengaged position, e.g., by actuating handle 1208 as shown in
The device then may be fully deployed by pulling the sheath proximally causing the second flared end region to flank the left side of the atrial septum and the neck of the device to lodge in the puncture through the fossa ovalis, and allowing expansion of the first flared end of the device into the right atrium as shown in
It should be noted that the inventive devices also may be used with patients having disorders other than heart failure. For example, in one embodiment the device may be implanted in a subject suffering from myocardial infarction, for example in the period immediately following myocardial infarction (e.g., within a few days of the event, or within two weeks of the event, or even within six months of the event). During such a period, the heart remodels to compensate for reduced myocardial function. For some subjects suffering from severe myocardial infarction, such remodeling may cause the function of the left ventricle to significantly deteriorate, which may lead to development of heart failure. Implanting an inventive device during the period immediately following myocardial infarction may inhibit such deterioration in the left ventricle by reducing LAP and LVEDP during the remodeling period. For example, in the above-described Example, heart failure was induced in the sheep by injecting microspheres that block the coronary artery and induce myocardial infarction. Following the myocardial infarction, the sheep developed heart failure. As can be seen in the various results for the implanted animals, implanting the inventive device even a week following the myocardial infarction inhibited degradation of the heart and yielded significantly improved mortality rates and cardiac functioning both immediately and over time as the subjects' hearts remodeled. As such, it is believed that implanting an inventive device for even a few weeks or months following myocardial infarction may provide significant benefits to the subject as their heart remodels. The device optionally then may be removed.
While various illustrative embodiments of the invention are described above, it will be apparent to one skilled in the art that various changes and modifications may be made herein without departing from the invention. It will further be appreciated that the devices described herein may be implanted in other positions in the heart. For example, device 100 illustrated in
This application is a continuation patent application of U.S. patent application Ser. No. 15/656,936, filed Jul. 21, 2017, now U.S. Pat. No. 10,478,594, which is a continuation of U.S. patent application Ser. No. 14/282,615, filed May 20, 2014, now U.S. Pat. No. 9,713,696, which claims the benefit of priority to U.S. Provisional Application Ser. No. 61/825,931, filed May 21, 2013, the contents of each of which are incorporated herein by reference in their entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3852334 | Dusza et al. | Dec 1974 | A |
| 3874388 | King et al. | Apr 1975 | A |
| 3952334 | Bokros et al. | Apr 1976 | A |
| 4364395 | Redmond | Dec 1982 | A |
| 4484955 | Hochstein | Nov 1984 | A |
| 4601309 | Chang | Jul 1986 | A |
| 4617932 | Kornberg | Oct 1986 | A |
| 4662355 | Pieronne et al. | May 1987 | A |
| 4665906 | Jervis | May 1987 | A |
| 4705507 | Boyles | Nov 1987 | A |
| 4836204 | Landymore et al. | Jun 1989 | A |
| 4979955 | Smith | Dec 1990 | A |
| 4988339 | Vadher | Jan 1991 | A |
| 4995857 | Arnold | Feb 1991 | A |
| 5035702 | Taheri | Jul 1991 | A |
| 5035706 | Giantureo et al. | Jul 1991 | A |
| 5037427 | Harada et al. | Aug 1991 | A |
| 5089005 | Harada | Feb 1992 | A |
| 5186431 | Tamari | Feb 1993 | A |
| 5197978 | Hess | Mar 1993 | A |
| 5234447 | Kaster et al. | Aug 1993 | A |
| 5267940 | Moulder | Dec 1993 | A |
| 5290227 | Pasque | Mar 1994 | A |
| 5312341 | Turi | May 1994 | A |
| 5326374 | Ilbawi et al. | Jul 1994 | A |
| 5332402 | Teitelbaum | Jul 1994 | A |
| 5334217 | Das | Aug 1994 | A |
| 5378239 | Termin et al. | Jan 1995 | A |
| 5409019 | Wilk | Apr 1995 | A |
| 5429144 | Wilk | Jul 1995 | A |
| 5500015 | Deac | Mar 1996 | A |
| 5531759 | Kensey et al. | Jul 1996 | A |
| 5545210 | Hess et al. | Aug 1996 | A |
| 5556386 | Todd | Sep 1996 | A |
| 5578008 | Hara | Nov 1996 | A |
| 5584803 | Stevens et al. | Dec 1996 | A |
| 5597377 | Aldea | Jan 1997 | A |
| 5645559 | Hachtman et al. | Jul 1997 | A |
| 5655548 | Nelson et al. | Aug 1997 | A |
| 5662711 | Douglas | Sep 1997 | A |
| 5702412 | Popov et al. | Dec 1997 | A |
| 5725552 | Kotula et al. | Mar 1998 | A |
| 5741324 | Glastra | Apr 1998 | A |
| 5749880 | Banas et al. | May 1998 | A |
| 5779716 | Cano et al. | Jul 1998 | A |
| 5795307 | Krueger | Aug 1998 | A |
| 5810836 | Hussein et al. | Sep 1998 | A |
| 5824062 | Patke et al. | Oct 1998 | A |
| 5824071 | Nelson et al. | Oct 1998 | A |
| 5846261 | Kotula et al. | Dec 1998 | A |
| 5910144 | Hayashi | Jun 1999 | A |
| 5916193 | Stevens et al. | Jun 1999 | A |
| 5941850 | Shah et al. | Aug 1999 | A |
| 5957949 | Leonhardt et al. | Sep 1999 | A |
| 5990379 | Gregory | Nov 1999 | A |
| 6027518 | Gaber | Feb 2000 | A |
| 6039755 | Edwin et al. | Mar 2000 | A |
| 6039759 | Carpentier et al. | Mar 2000 | A |
| 6086610 | Duerig et al. | Jul 2000 | A |
| 6111520 | Allen et al. | Aug 2000 | A |
| 6117159 | Huebsch et al. | Sep 2000 | A |
| 6120534 | Ruiz | Sep 2000 | A |
| 6124523 | Banas et al. | Sep 2000 | A |
| 6126686 | Badylak et al. | Oct 2000 | A |
| 6165188 | Saadat et al. | Dec 2000 | A |
| 6210318 | Lederman | Apr 2001 | B1 |
| 6214039 | Banas et al. | Apr 2001 | B1 |
| 6217541 | Yu | Apr 2001 | B1 |
| 6221096 | Aiba et al. | Apr 2001 | B1 |
| 6231587 | Makower | May 2001 | B1 |
| 6242762 | Brown et al. | Jun 2001 | B1 |
| 6245099 | Edwin et al. | Jun 2001 | B1 |
| 6254564 | Wilk et al. | Jul 2001 | B1 |
| 6260552 | Mortier et al. | Jul 2001 | B1 |
| 6264684 | Banas et al. | Jul 2001 | B1 |
| 6270515 | Linden et al. | Aug 2001 | B1 |
| 6270526 | Cox | Aug 2001 | B1 |
| 6277078 | Porat et al. | Aug 2001 | B1 |
| 6278379 | Allen et al. | Aug 2001 | B1 |
| 6290728 | Phelps | Sep 2001 | B1 |
| 6302892 | Wilk | Oct 2001 | B1 |
| 6306141 | Jervis | Oct 2001 | B1 |
| 6328699 | Eigler et al. | Dec 2001 | B1 |
| 6344022 | Jarvik | Feb 2002 | B1 |
| 6358277 | Duran | Mar 2002 | B1 |
| 6391036 | Berg et al. | May 2002 | B1 |
| 6398803 | Layne et al. | Jun 2002 | B1 |
| 6406422 | Landesberg | Jun 2002 | B1 |
| 6447539 | Nelson et al. | Sep 2002 | B1 |
| 6451051 | Drasler et al. | Sep 2002 | B2 |
| 6458153 | Bailey et al. | Oct 2002 | B1 |
| 6468303 | Amplatz et al. | Oct 2002 | B1 |
| 6475136 | Forsell | Nov 2002 | B1 |
| 6478776 | Rosenman et al. | Nov 2002 | B1 |
| 6485507 | Walak et al. | Nov 2002 | B1 |
| 6488702 | Besselink | Dec 2002 | B1 |
| 6491705 | Gifford et al. | Dec 2002 | B2 |
| 6527698 | Kung et al. | Mar 2003 | B1 |
| 6544208 | Ethier et al. | Apr 2003 | B2 |
| 6547814 | Edwin et al. | Apr 2003 | B2 |
| 6562066 | Martin | May 2003 | B1 |
| 6572652 | Shaknovich | Jun 2003 | B2 |
| 6579314 | Lombardi et al. | Jun 2003 | B1 |
| 6589198 | Soltanpour et al. | Jul 2003 | B1 |
| 6616675 | Evard et al. | Sep 2003 | B1 |
| 6632169 | Korakianitis et al. | Oct 2003 | B2 |
| 6638303 | Campbell | Oct 2003 | B1 |
| 6641610 | Wolf et al. | Nov 2003 | B2 |
| 6652578 | Bailey et al. | Nov 2003 | B2 |
| 6685664 | Levin et al. | Feb 2004 | B2 |
| 6712836 | Berg et al. | Mar 2004 | B1 |
| 6740115 | Lombardi et al. | May 2004 | B2 |
| 6758858 | McCrea et al. | Jul 2004 | B2 |
| 6764507 | Shanley et al. | Jul 2004 | B2 |
| 6770087 | Layne et al. | Aug 2004 | B2 |
| 6797217 | McCrea et al. | Sep 2004 | B2 |
| 6890350 | Walak | May 2005 | B1 |
| 6923829 | Boyle et al. | Aug 2005 | B2 |
| 6970742 | Mann et al. | Nov 2005 | B2 |
| 7001409 | Amplatz | Feb 2006 | B2 |
| 7004966 | Edwin et al. | Feb 2006 | B2 |
| 7025777 | Moore | Apr 2006 | B2 |
| 7060150 | Banas et al. | Jun 2006 | B2 |
| 7083640 | Lombardi et al. | Aug 2006 | B2 |
| 7115095 | Eigler et al. | Oct 2006 | B2 |
| 7118600 | Dua et al. | Oct 2006 | B2 |
| 7137953 | Eigler et al. | Nov 2006 | B2 |
| 7147604 | Allen et al. | Dec 2006 | B1 |
| 7149587 | Wardle et al. | Dec 2006 | B2 |
| 7169160 | Middleman et al. | Jan 2007 | B1 |
| 7169172 | Levine et al. | Jan 2007 | B2 |
| 7195594 | Eigler et al. | Mar 2007 | B2 |
| 7208010 | Shanley et al. | Apr 2007 | B2 |
| 7226558 | Nieman et al. | Jun 2007 | B2 |
| 7245117 | Joy et al. | Jul 2007 | B1 |
| 7294115 | Wilk | Nov 2007 | B1 |
| 7306756 | Edwin et al. | Dec 2007 | B2 |
| 7402899 | Whiting et al. | Jul 2008 | B1 |
| 7439723 | Allen et al. | Oct 2008 | B2 |
| 7468071 | Edwin et al. | Dec 2008 | B2 |
| 7483743 | Mann et al. | Jan 2009 | B2 |
| 7498799 | Allen et al. | Mar 2009 | B2 |
| 7509169 | Eigler et al. | Mar 2009 | B2 |
| 7550978 | Joy et al. | Jun 2009 | B2 |
| 7578899 | Edwin et al. | Aug 2009 | B2 |
| 7590449 | Mann et al. | Sep 2009 | B2 |
| 7615010 | Najafi et al. | Nov 2009 | B1 |
| 7621879 | Eigler et al. | Nov 2009 | B2 |
| 7679355 | Allen et al. | Mar 2010 | B2 |
| 7717854 | Mann et al. | May 2010 | B2 |
| 7794473 | Tessmer et al. | Sep 2010 | B2 |
| 7839153 | Joy et al. | Nov 2010 | B2 |
| 7842083 | Shanley et al. | Nov 2010 | B2 |
| 7854172 | O'Brien et al. | Dec 2010 | B2 |
| 7862513 | Eigler et al. | Jan 2011 | B2 |
| 7914639 | Layne et al. | Mar 2011 | B2 |
| 7939000 | Edwin et al. | May 2011 | B2 |
| 7988724 | Salahieh et al. | Aug 2011 | B2 |
| 7993383 | Hartley et al. | Aug 2011 | B2 |
| 8012194 | Edwin et al. | Sep 2011 | B2 |
| 8016877 | Seguin et al. | Sep 2011 | B2 |
| 8021420 | Dolan | Sep 2011 | B2 |
| 8025625 | Allen | Sep 2011 | B2 |
| 8025668 | McCartney | Sep 2011 | B2 |
| 8043360 | McNamara et al. | Oct 2011 | B2 |
| 8070708 | Rottenberg et al. | Dec 2011 | B2 |
| 8091556 | Keren et al. | Jan 2012 | B2 |
| 8096959 | Stewart et al. | Jan 2012 | B2 |
| 8137605 | McCrea et al. | Mar 2012 | B2 |
| 8142363 | Eigler et al. | Mar 2012 | B1 |
| 8147545 | Avior | Apr 2012 | B2 |
| 8157852 | Bloom et al. | Apr 2012 | B2 |
| 8157860 | McNamara et al. | Apr 2012 | B2 |
| 8157940 | Edwin et al. | Apr 2012 | B2 |
| 8158041 | Colone | Apr 2012 | B2 |
| 8187321 | Shanley et al. | May 2012 | B2 |
| 8202313 | Shanley et al. | Jun 2012 | B2 |
| 8206435 | Shanley et al. | Jun 2012 | B2 |
| 8216398 | Bledsoe et al. | Jul 2012 | B2 |
| 8235916 | Whiting et al. | Aug 2012 | B2 |
| 8235933 | Keren et al. | Aug 2012 | B2 |
| 8246677 | Ryan | Aug 2012 | B2 |
| 8287589 | Otto et al. | Oct 2012 | B2 |
| 8298150 | Mann et al. | Oct 2012 | B2 |
| 8298244 | Garcia et al. | Oct 2012 | B2 |
| 8303511 | Eigler et al. | Nov 2012 | B2 |
| 8313524 | Edwin et al. | Nov 2012 | B2 |
| 8328751 | Keren et al. | Dec 2012 | B2 |
| 8337650 | Edwin et al. | Dec 2012 | B2 |
| 8348996 | Tuval et al. | Jan 2013 | B2 |
| 8357193 | Phan et al. | Jan 2013 | B2 |
| 8398708 | Meiri et al. | Mar 2013 | B2 |
| 8460366 | Rowe | Jun 2013 | B2 |
| 8468667 | Straubinger et al. | Jun 2013 | B2 |
| 8480594 | Eigler et al. | Jul 2013 | B2 |
| 8579966 | Seguin et al. | Nov 2013 | B2 |
| 8597225 | Kapadia | Dec 2013 | B2 |
| 8617337 | Layne et al. | Dec 2013 | B2 |
| 8617441 | Edwin et al. | Dec 2013 | B2 |
| 8652284 | Bogert et al. | Feb 2014 | B2 |
| 8665086 | Miller et al. | Mar 2014 | B2 |
| 8696611 | Nitzan et al. | Apr 2014 | B2 |
| 8790241 | Edwin et al. | Jul 2014 | B2 |
| 8882697 | Celermajer et al. | Nov 2014 | B2 |
| 8882798 | Schwab et al. | Nov 2014 | B2 |
| 8911489 | Ben-Muvhar | Dec 2014 | B2 |
| 9005155 | Sugimoto | Apr 2015 | B2 |
| 9034034 | Nitzan et al. | May 2015 | B2 |
| 9055917 | Mann et al. | Jun 2015 | B2 |
| 9060696 | Eigler et al. | Jun 2015 | B2 |
| 9067050 | Gallagher et al. | Jun 2015 | B2 |
| 9205236 | McNamara et al. | Dec 2015 | B2 |
| 9220429 | Nabutovsky et al. | Dec 2015 | B2 |
| 9358371 | McNamara et al. | Jun 2016 | B2 |
| 9393115 | Tabor et al. | Jul 2016 | B2 |
| 9456812 | Finch et al. | Oct 2016 | B2 |
| 9622895 | Cohen et al. | Apr 2017 | B2 |
| 9629715 | Nitzan et al. | Apr 2017 | B2 |
| 9681948 | Levi et al. | Jun 2017 | B2 |
| 9707382 | Nitzan et al. | Jul 2017 | B2 |
| 9713696 | Yacoby et al. | Jul 2017 | B2 |
| 9724499 | Rottenberg et al. | Aug 2017 | B2 |
| 9757107 | McNamara et al. | Sep 2017 | B2 |
| 9789294 | Taft et al. | Oct 2017 | B2 |
| 9918677 | Eigler et al. | Mar 2018 | B2 |
| 9943670 | Keren et al. | Apr 2018 | B2 |
| 9980815 | Nitzan et al. | May 2018 | B2 |
| 10045766 | McNamara et al. | Aug 2018 | B2 |
| 10047421 | Khan et al. | Aug 2018 | B2 |
| 10076403 | Eigler et al. | Sep 2018 | B1 |
| 10105103 | Goldshtein et al. | Oct 2018 | B2 |
| 10111741 | Michalak | Oct 2018 | B2 |
| 10207087 | Keren et al. | Feb 2019 | B2 |
| 10251750 | Eigler et al. | Apr 2019 | B2 |
| 10265169 | Desrosiers et al. | Apr 2019 | B2 |
| 10299687 | Nabutovsky et al. | May 2019 | B2 |
| 10357320 | Beira | Jul 2019 | B2 |
| 10357357 | Levi et al. | Jul 2019 | B2 |
| 10368981 | Nitzan et al. | Aug 2019 | B2 |
| 10463490 | Rottenberg et al. | Nov 2019 | B2 |
| 10478594 | Yacoby et al. | Nov 2019 | B2 |
| 10548725 | Alkhatib et al. | Feb 2020 | B2 |
| 10561423 | Sharma | Feb 2020 | B2 |
| 10583002 | Lane et al. | Mar 2020 | B2 |
| 10639459 | Nitzan et al. | May 2020 | B2 |
| 10828151 | Nitzan et al. | Nov 2020 | B2 |
| 10835394 | Nae et al. | Nov 2020 | B2 |
| 10898698 | Eigler et al. | Jan 2021 | B1 |
| 10912645 | Rottenberg et al. | Feb 2021 | B2 |
| 10925706 | Eigler et al. | Feb 2021 | B2 |
| 10940296 | Keren | Mar 2021 | B2 |
| 11109988 | Rosen et al. | Sep 2021 | B2 |
| 11234702 | Eigler et al. | Feb 2022 | B1 |
| 11253353 | Levi et al. | Feb 2022 | B2 |
| 11291807 | Eigler et al. | Apr 2022 | B2 |
| 11304831 | Nae et al. | Apr 2022 | B2 |
| 20010021872 | Bailey et al. | Sep 2001 | A1 |
| 20020099431 | Armstrong | Jul 2002 | A1 |
| 20020120277 | Hauschild et al. | Aug 2002 | A1 |
| 20020165479 | Wilk | Nov 2002 | A1 |
| 20020165606 | Wolf et al. | Nov 2002 | A1 |
| 20020169371 | Gilderdale | Nov 2002 | A1 |
| 20020169377 | Khairkhahan et al. | Nov 2002 | A1 |
| 20020173742 | Keren et al. | Nov 2002 | A1 |
| 20020183628 | Reich et al. | Dec 2002 | A1 |
| 20030028213 | Thill et al. | Feb 2003 | A1 |
| 20030045902 | Weadock | Mar 2003 | A1 |
| 20030069606 | Girouard | Apr 2003 | A1 |
| 20030100920 | Akin et al. | May 2003 | A1 |
| 20030125798 | Martin | Jul 2003 | A1 |
| 20030136417 | Fonseca et al. | Jul 2003 | A1 |
| 20030139819 | Beer et al. | Jul 2003 | A1 |
| 20030176914 | Rabkin et al. | Sep 2003 | A1 |
| 20030209835 | Chun et al. | Nov 2003 | A1 |
| 20030216679 | Wolf et al. | Nov 2003 | A1 |
| 20030216803 | Ledergerber | Nov 2003 | A1 |
| 20040010219 | McCusker et al. | Jan 2004 | A1 |
| 20040016514 | Nien | Jan 2004 | A1 |
| 20040073242 | Chanduszko | Apr 2004 | A1 |
| 20040077988 | Tweden et al. | Apr 2004 | A1 |
| 20040088045 | Cox | May 2004 | A1 |
| 20040093075 | Kuehne | May 2004 | A1 |
| 20040102797 | Golden et al. | May 2004 | A1 |
| 20040116999 | Ledergerber | Jun 2004 | A1 |
| 20040138743 | Myers et al. | Jul 2004 | A1 |
| 20040147869 | Wolf et al. | Jul 2004 | A1 |
| 20040147871 | Burnett | Jul 2004 | A1 |
| 20040147886 | Bonni | Jul 2004 | A1 |
| 20040147969 | Mann et al. | Jul 2004 | A1 |
| 20040162514 | Alferness et al. | Aug 2004 | A1 |
| 20040193261 | Berreklouw | Sep 2004 | A1 |
| 20040210190 | Kohler et al. | Oct 2004 | A1 |
| 20040210307 | Khairkhahan | Oct 2004 | A1 |
| 20040225352 | Osborne et al. | Nov 2004 | A1 |
| 20050003327 | Elian et al. | Jan 2005 | A1 |
| 20050033327 | Gainor et al. | Feb 2005 | A1 |
| 20050033351 | Newton | Feb 2005 | A1 |
| 20050065589 | Schneider et al. | Mar 2005 | A1 |
| 20050125032 | Whisenant et al. | Jun 2005 | A1 |
| 20050137682 | Justino | Jun 2005 | A1 |
| 20050148925 | Rottenberg et al. | Jul 2005 | A1 |
| 20050165344 | Dobak, III | Jul 2005 | A1 |
| 20050182486 | Gabbay | Aug 2005 | A1 |
| 20050267524 | Chanduszko | Dec 2005 | A1 |
| 20050283231 | Haug et al. | Dec 2005 | A1 |
| 20050288596 | Eigler et al. | Dec 2005 | A1 |
| 20050288706 | Widomski et al. | Dec 2005 | A1 |
| 20050288786 | Chanduszko | Dec 2005 | A1 |
| 20060009800 | Christianson et al. | Jan 2006 | A1 |
| 20060025857 | Bergheim et al. | Feb 2006 | A1 |
| 20060052821 | Abbott et al. | Mar 2006 | A1 |
| 20060111660 | Wolf et al. | May 2006 | A1 |
| 20060116710 | Corcoran et al. | Jun 2006 | A1 |
| 20060122522 | Chavan et al. | Jun 2006 | A1 |
| 20060122647 | Callaghan et al. | Jun 2006 | A1 |
| 20060167541 | Lattouf | Jul 2006 | A1 |
| 20060184231 | Rucker | Aug 2006 | A1 |
| 20060212110 | Osborne et al. | Sep 2006 | A1 |
| 20060241745 | Solem | Oct 2006 | A1 |
| 20060256611 | Bednorz et al. | Nov 2006 | A1 |
| 20060282157 | Hill et al. | Dec 2006 | A1 |
| 20070010852 | Blaeser et al. | Jan 2007 | A1 |
| 20070021739 | Weber | Jan 2007 | A1 |
| 20070043435 | Seguin et al. | Feb 2007 | A1 |
| 20070073337 | Abbott et al. | Mar 2007 | A1 |
| 20070129756 | Abbott et al. | Jun 2007 | A1 |
| 20070191863 | De Juan et al. | Aug 2007 | A1 |
| 20070213813 | Von Segesser et al. | Sep 2007 | A1 |
| 20070249985 | Brenneman et al. | Oct 2007 | A1 |
| 20070276413 | Nobles | Nov 2007 | A1 |
| 20070276414 | Nobles | Nov 2007 | A1 |
| 20070282157 | Rottenberg et al. | Dec 2007 | A1 |
| 20070299384 | Faul et al. | Dec 2007 | A1 |
| 20080034836 | Eigler et al. | Feb 2008 | A1 |
| 20080086205 | Gordy et al. | Apr 2008 | A1 |
| 20080125861 | Webler et al. | May 2008 | A1 |
| 20080171944 | Brenneman et al. | Jul 2008 | A1 |
| 20080177300 | Mas et al. | Jul 2008 | A1 |
| 20080262602 | Wilk et al. | Oct 2008 | A1 |
| 20080319525 | Tieu et al. | Dec 2008 | A1 |
| 20090030499 | Bebb et al. | Jan 2009 | A1 |
| 20090054976 | Tuval et al. | Feb 2009 | A1 |
| 20090125104 | Hoffman | May 2009 | A1 |
| 20090149947 | Frohwitter | Jun 2009 | A1 |
| 20090198315 | Boudjemline | Aug 2009 | A1 |
| 20090276040 | Rowe et al. | Nov 2009 | A1 |
| 20090319037 | Rowe et al. | Dec 2009 | A1 |
| 20100004740 | Seguin et al. | Jan 2010 | A1 |
| 20100022940 | Thompson | Jan 2010 | A1 |
| 20100057192 | Celermajer | Mar 2010 | A1 |
| 20100069836 | Satake | Mar 2010 | A1 |
| 20100070022 | Kuehling | Mar 2010 | A1 |
| 20100081867 | Fishler et al. | Apr 2010 | A1 |
| 20100100167 | Bortlein et al. | Apr 2010 | A1 |
| 20100121434 | Paul et al. | May 2010 | A1 |
| 20100179590 | Fortson et al. | Jul 2010 | A1 |
| 20100191326 | Alkhatib | Jul 2010 | A1 |
| 20100249909 | McNamara et al. | Sep 2010 | A1 |
| 20100249910 | McNamara et al. | Sep 2010 | A1 |
| 20100249915 | Zhang | Sep 2010 | A1 |
| 20100256548 | McNamara et al. | Oct 2010 | A1 |
| 20100256753 | McNamara et al. | Oct 2010 | A1 |
| 20100298755 | McNamara et al. | Nov 2010 | A1 |
| 20100324652 | Aurilia et al. | Dec 2010 | A1 |
| 20110022057 | Eigler et al. | Jan 2011 | A1 |
| 20110022157 | Essinger et al. | Jan 2011 | A1 |
| 20110054515 | Bridgeman et al. | Mar 2011 | A1 |
| 20110071623 | Finch et al. | Mar 2011 | A1 |
| 20110071624 | Finch et al. | Mar 2011 | A1 |
| 20110093059 | Fischell et al. | Apr 2011 | A1 |
| 20110152923 | Fox | Jun 2011 | A1 |
| 20110190874 | Celermajer et al. | Aug 2011 | A1 |
| 20110218479 | Rottenberg et al. | Sep 2011 | A1 |
| 20110218480 | Rottenberg et al. | Sep 2011 | A1 |
| 20110218481 | Rottenberg et al. | Sep 2011 | A1 |
| 20110257723 | McNamara | Oct 2011 | A1 |
| 20110264203 | Dwork et al. | Oct 2011 | A1 |
| 20110276086 | Al-Qbandi et al. | Nov 2011 | A1 |
| 20110295182 | Finch et al. | Dec 2011 | A1 |
| 20110295183 | Finch et al. | Dec 2011 | A1 |
| 20110295362 | Finch et al. | Dec 2011 | A1 |
| 20110295366 | Finch et al. | Dec 2011 | A1 |
| 20110306916 | Nitzan et al. | Dec 2011 | A1 |
| 20110319806 | Wardle | Dec 2011 | A1 |
| 20120022507 | Najafi et al. | Jan 2012 | A1 |
| 20120022633 | Olson et al. | Jan 2012 | A1 |
| 20120035590 | Whiting et al. | Feb 2012 | A1 |
| 20120041422 | Whiting et al. | Feb 2012 | A1 |
| 20120046528 | Eigler et al. | Feb 2012 | A1 |
| 20120046739 | Von Oepen et al. | Feb 2012 | A1 |
| 20120053686 | McNamara et al. | Mar 2012 | A1 |
| 20120071918 | Amin et al. | Mar 2012 | A1 |
| 20120130301 | McNamara et al. | May 2012 | A1 |
| 20120165928 | Nitzan et al. | Jun 2012 | A1 |
| 20120179172 | Paul et al. | Jul 2012 | A1 |
| 20120190991 | Bornzin et al. | Jul 2012 | A1 |
| 20120265296 | McNamara et al. | Oct 2012 | A1 |
| 20120271398 | Essinger et al. | Oct 2012 | A1 |
| 20120289882 | McNamara et al. | Nov 2012 | A1 |
| 20120290062 | McNamara et al. | Nov 2012 | A1 |
| 20130030521 | Nitzan et al. | Jan 2013 | A1 |
| 20130046373 | Cartledge et al. | Feb 2013 | A1 |
| 20130096965 | Pappas et al. | Apr 2013 | A1 |
| 20130138145 | Von Oepen | May 2013 | A1 |
| 20130178783 | McNamara et al. | Jul 2013 | A1 |
| 20130178784 | McNamara et al. | Jul 2013 | A1 |
| 20130184633 | McNamara et al. | Jul 2013 | A1 |
| 20130184634 | McNamara et al. | Jul 2013 | A1 |
| 20130197423 | Keren et al. | Aug 2013 | A1 |
| 20130197547 | Fukuoka et al. | Aug 2013 | A1 |
| 20130197629 | Gainor et al. | Aug 2013 | A1 |
| 20130204175 | Sugimoto | Aug 2013 | A1 |
| 20130231737 | McNamara et al. | Sep 2013 | A1 |
| 20130261531 | Gallagher et al. | Oct 2013 | A1 |
| 20130281988 | Magnin et al. | Oct 2013 | A1 |
| 20130304192 | Chanduszko | Nov 2013 | A1 |
| 20130331864 | Jelich | Dec 2013 | A1 |
| 20140012181 | Sugimoto et al. | Jan 2014 | A1 |
| 20140012303 | Heipl | Jan 2014 | A1 |
| 20140012368 | Sugimoto et al. | Jan 2014 | A1 |
| 20140012369 | Murry, III et al. | Jan 2014 | A1 |
| 20140067037 | Fargahi | Mar 2014 | A1 |
| 20140094904 | Salahieh et al. | Apr 2014 | A1 |
| 20140128795 | Keren et al. | May 2014 | A1 |
| 20140128796 | Keren et al. | May 2014 | A1 |
| 20140163449 | Rottenberg et al. | Jun 2014 | A1 |
| 20140194971 | McNamara | Jul 2014 | A1 |
| 20140213959 | Nitzan et al. | Jul 2014 | A1 |
| 20140222144 | Eberhardt et al. | Aug 2014 | A1 |
| 20140249621 | Eidenschink | Sep 2014 | A1 |
| 20140257167 | Celermajer | Sep 2014 | A1 |
| 20140275916 | Nabutovsky et al. | Sep 2014 | A1 |
| 20140277045 | Fazio et al. | Sep 2014 | A1 |
| 20140277054 | McNamara et al. | Sep 2014 | A1 |
| 20140303710 | Zhang et al. | Oct 2014 | A1 |
| 20140350565 | Yacoby et al. | Nov 2014 | A1 |
| 20140350658 | Benary et al. | Nov 2014 | A1 |
| 20140350661 | Schaeffer | Nov 2014 | A1 |
| 20140350669 | Gillespie et al. | Nov 2014 | A1 |
| 20140357946 | Golden et al. | Dec 2014 | A1 |
| 20150005810 | Center et al. | Jan 2015 | A1 |
| 20150034217 | Vad | Feb 2015 | A1 |
| 20150039084 | Levi et al. | Feb 2015 | A1 |
| 20150066140 | Quadri et al. | Mar 2015 | A1 |
| 20150073539 | Geiger et al. | Mar 2015 | A1 |
| 20150112383 | Sherman et al. | Apr 2015 | A1 |
| 20150119796 | Finch | Apr 2015 | A1 |
| 20150127093 | Hosmer et al. | May 2015 | A1 |
| 20150142049 | Delgado et al. | May 2015 | A1 |
| 20150148731 | McNamara et al. | May 2015 | A1 |
| 20150148896 | Karapetian et al. | May 2015 | A1 |
| 20150157455 | Hoang et al. | Jun 2015 | A1 |
| 20150173897 | Raanani et al. | Jun 2015 | A1 |
| 20150182334 | Bourang et al. | Jul 2015 | A1 |
| 20150190229 | Seguin | Jul 2015 | A1 |
| 20150196383 | Johnson | Jul 2015 | A1 |
| 20150201998 | Roy et al. | Jul 2015 | A1 |
| 20150209143 | Duffy et al. | Jul 2015 | A1 |
| 20150230924 | Miller et al. | Aug 2015 | A1 |
| 20150238314 | Bortlein et al. | Aug 2015 | A1 |
| 20150245908 | Nitzan et al. | Sep 2015 | A1 |
| 20150272731 | Racchini et al. | Oct 2015 | A1 |
| 20150282790 | Quinn et al. | Oct 2015 | A1 |
| 20150282931 | Brunnett et al. | Oct 2015 | A1 |
| 20150294313 | Kamal et al. | Oct 2015 | A1 |
| 20150313599 | Johnson et al. | Nov 2015 | A1 |
| 20150359556 | Vardi | Dec 2015 | A1 |
| 20160007924 | Eigler et al. | Jan 2016 | A1 |
| 20160022423 | McNamara et al. | Jan 2016 | A1 |
| 20160022970 | Forcucci et al. | Jan 2016 | A1 |
| 20160073907 | Nabutovsky et al. | Mar 2016 | A1 |
| 20160120550 | McNamara et al. | May 2016 | A1 |
| 20160129260 | Mann et al. | May 2016 | A1 |
| 20160157862 | Hernandez et al. | Jun 2016 | A1 |
| 20160166381 | Sugimoto et al. | Jun 2016 | A1 |
| 20160184561 | McNamara et al. | Jun 2016 | A9 |
| 20160206423 | O'Connor et al. | Jul 2016 | A1 |
| 20160213467 | Backus et al. | Jul 2016 | A1 |
| 20160220360 | Lin et al. | Aug 2016 | A1 |
| 20160220365 | Backus et al. | Aug 2016 | A1 |
| 20160262878 | Backus et al. | Sep 2016 | A1 |
| 20160262879 | Meiri et al. | Sep 2016 | A1 |
| 20160287386 | Alon et al. | Oct 2016 | A1 |
| 20160296325 | Edelman et al. | Oct 2016 | A1 |
| 20160361167 | Tuval et al. | Dec 2016 | A1 |
| 20160361184 | Tabor et al. | Dec 2016 | A1 |
| 20170035435 | Amin et al. | Feb 2017 | A1 |
| 20170056171 | Cooper et al. | Mar 2017 | A1 |
| 20170113026 | Finch | Apr 2017 | A1 |
| 20170128705 | Forcucci et al. | May 2017 | A1 |
| 20170135685 | McNamara et al. | May 2017 | A9 |
| 20170165532 | Khan et al. | Jun 2017 | A1 |
| 20170216025 | Nitzan et al. | Aug 2017 | A1 |
| 20170224323 | Rowe et al. | Aug 2017 | A1 |
| 20170224444 | Viecilli et al. | Aug 2017 | A1 |
| 20170231766 | Hariton et al. | Aug 2017 | A1 |
| 20170273790 | Vettukattil et al. | Sep 2017 | A1 |
| 20170281339 | Levi et al. | Oct 2017 | A1 |
| 20170312486 | Nitzan et al. | Nov 2017 | A1 |
| 20170319823 | Yacoby et al. | Nov 2017 | A1 |
| 20170325956 | Rottenberg et al. | Nov 2017 | A1 |
| 20170348100 | Lane et al. | Dec 2017 | A1 |
| 20180099128 | McNamara et al. | Apr 2018 | A9 |
| 20180104053 | Alkhatib et al. | Apr 2018 | A1 |
| 20180110609 | Ehnes et al. | Apr 2018 | A1 |
| 20180125630 | Hynes et al. | May 2018 | A1 |
| 20180130988 | Nishikawa et al. | May 2018 | A1 |
| 20180243071 | Eigler et al. | Aug 2018 | A1 |
| 20180256865 | Finch et al. | Sep 2018 | A1 |
| 20180263766 | Nitzan et al. | Sep 2018 | A1 |
| 20180344994 | Karavany et al. | Dec 2018 | A1 |
| 20190000327 | Doan et al. | Jan 2019 | A1 |
| 20190008628 | Eigler et al. | Jan 2019 | A1 |
| 20190015103 | Sharma | Jan 2019 | A1 |
| 20190015188 | Eigler et al. | Jan 2019 | A1 |
| 20190021861 | Finch | Jan 2019 | A1 |
| 20190239754 | Nabutovsky et al. | Aug 2019 | A1 |
| 20190328513 | Levi et al. | Oct 2019 | A1 |
| 20190336163 | McNamara et al. | Nov 2019 | A1 |
| 20200060825 | Rottenberg et al. | Feb 2020 | A1 |
| 20200085600 | Schwartz et al. | Mar 2020 | A1 |
| 20200197178 | Vecchio | Jun 2020 | A1 |
| 20200261705 | Nitzan et al. | Aug 2020 | A1 |
| 20200315599 | Nae et al. | Oct 2020 | A1 |
| 20200368505 | Nae et al. | Nov 2020 | A1 |
| 20210052378 | Nitzan et al. | Feb 2021 | A1 |
| 20220211361 | Rolando et al. | Jul 2022 | A1 |
| 20220304803 | Guyenot et al. | Sep 2022 | A1 |
| Number | Date | Country |
|---|---|---|
| 2003291117 | Apr 2009 | AU |
| 2378920 | Feb 2001 | CA |
| 1987777 | Nov 2008 | EP |
| 2238933 | Oct 2010 | EP |
| 2305321 | Apr 2011 | EP |
| 1965842 | Nov 2011 | EP |
| 3400907 | Nov 2018 | EP |
| 2827153 | Jan 2003 | FR |
| WO-9531945 | Nov 1995 | WO |
| WO-9727898 | Aug 1997 | WO |
| WO-9960941 | Dec 1999 | WO |
| WO-0044311 | Aug 2000 | WO |
| WO-0050100 | Aug 2000 | WO |
| WO-0110314 | Feb 2001 | WO |
| WO-0126585 | Apr 2001 | WO |
| WO-0226281 | Apr 2002 | WO |
| WO-02071974 | Sep 2002 | WO |
| WO-02087473 | Nov 2002 | WO |
| WO-03053495 | Jul 2003 | WO |
| WO-2005027752 | Mar 2005 | WO |
| WO-2005074367 | Aug 2005 | WO |
| WO-2006127765 | Nov 2006 | WO |
| WO-2007083288 | Jul 2007 | WO |
| WO-2008055301 | May 2008 | WO |
| WO-2008070797 | Jun 2008 | WO |
| WO-2009029261 | Mar 2009 | WO |
| WO-2010128501 | Nov 2010 | WO |
| WO-2010128501 | Nov 2010 | WO |
| WO-2010129089 | Nov 2010 | WO |
| WO-2010139771 | Dec 2010 | WO |
| WO-2011062858 | May 2011 | WO |
| WO-2013096965 | Jun 2013 | WO |
| WO-2016178171 | Nov 2016 | WO |
| WO-2017118920 | Jul 2017 | WO |
| WO-2018158747 | Sep 2018 | WO |
| WO-2019015617 | Jan 2019 | WO |
| WO-2019085841 | May 2019 | WO |
| WO-2019109013 | Jun 2019 | WO |
| WO-2019142152 | Jul 2019 | WO |
| WO-2019179447 | Sep 2019 | WO |
| WO-2019218072 | Nov 2019 | WO |
| WO-2020206062 | Oct 2020 | WO |
| WO-2020257530 | Dec 2020 | WO |
| WO-2021050589 | Mar 2021 | WO |
| WO-2021113670 | Jun 2021 | WO |
| WO-2021212011 | Oct 2021 | WO |
| WO-2022046921 | Mar 2022 | WO |
| WO-2022076601 | Apr 2022 | WO |
| WO-2022091018 | May 2022 | WO |
| WO-2022091019 | May 2022 | WO |
| Entry |
|---|
| Ando et al., “Left ventricular decompression through a patent foramen ovale in a patient with hypertropic cardiomyopathy: A case report,” Cardiovascular Ultrasound 2: 1-7 (2004). |
| Atrium Advanta V12, Balloon Expandable Covered Stent, Improving Patient Outcomes with an Endovascular Approach, Brochure—8 pages, Getinge (2017). |
| Braunwald, Heart Disease, Chapter 6, p. 186. |
| Bridges, et al., The Society of Thoracic Surgeons Practice Guideline Series: Transmyocardial Laser Revascularization, Ann Thorac Surg., 77:1494-1502 (2004). |
| Bristow et al., Improvement in cardiac myocite function by biological effects of medical therapy: a new concept in the treatment of heart failure, European Heart Journal 16 (Suppl.F): 20-31 (1995). |
| Case et al., “Relief of High Left-Atrial Pressure in Left-Ventricular Failure,” Lancet, pp. 841-842 (Oct. 14, 1964). |
| Coats et al., “Controlled trial of physical training in chronic heart failure: Exercise performance, hemodynamics, ventilation and autonomic function,” Circulation 85:2119-2131 (1992). |
| Partial International Search dated Aug. 17, 2017 in Int'l PCT Patent Appl. Serial No. PCT/IB2017/053188. |
| Davies et al., “Reduced contraction and altered frequency response of isolated ventricular myocytes from patients with heart failure,” Circulation 92: 2540-2549 (1995). |
| Ennezat et al., An unusual case of low-flow, low-gradient severe aortic stenosis: Left-to-right shunt due to atrial septal defect, Cardiology 113(2): 146-148 (2009). |
| Ewert et al., “Acute left heart failure after interventional occlusion of an atrial septal defect,” Z Kardiol. 90(5): 362-366 (May 2001). |
| Ewert et al., Masked Left Ventricular Restriction in Elderly Patients With Atrial Septal Defects: A Contraindication for Closure?, Catheterization and Cardiovascular Interventions 52: 177-180 (2001). |
| Extended EP Search Report dated Sep. 19, 2016 in EP Patent Application Serial No. 16170281.6. |
| Extended European Search Report dated Jan. 8, 2015 in EP Patent Appl No. 10772089.8. |
| Geiran et al., “Changes in cardiac dynamics by opening an interventricular shunt in dogs,” J. Surg. Res. 48(1): 6-12 (Jan. 1990). |
| Gelernter-Yaniv et al., “Transcatheter closure of left-to-right interatrial shunts to resolve hypoxemia,” Conginit. Heart Dis. 31(1) 47-53 (Jan. 2008). |
| Gewillig et al., “Creation with a stent of an unrestrictive lasting atrial communication,” Cardio. Young 12(4): 404-407 (2002). |
| International Search Report & Written Opinion dated May 29, 2018 in Int'l PCT Patent Appl. Serial No. PCTIB2018/051355. |
| International Search Report for PCT/IL2005/000131, 3 pages (dated Apr. 7, 2008). |
| International Search Report for PCT/IL2010/000354 dated Aug. 25, 2010 (1 pg). |
| Int'l Search Report & Written Opinion dated Feb. 16, 2015 in Int'l PCT Patent Appl. Serial No. PCT/IB2014/001771. |
| Khositseth et al., Transcatheter Amplatzer Device Closure of Atrial Septal Defect and Patent Foramen Ovale in Patients With Presumed Paradoxical Embolism, Mayo Clinic Proc., 79:35-41 (2004). |
| Kramer et al., “Controlled study of captopril in chronic heart failure: A rest and exercise hemodynamic study,” Circulation 67(4): 807-816 (1983). |
| Lai et al., Bidirectional Shunt Through a Residual Atrial Septal Defect After Percutaneous Transvenous Mitral Commissurotomy, Cardiology 83(3): 205-207 (1993). |
| Lemmer et al., “Surgical implications of atrial septal defect complicating aortic balloon valvuloplasty,” Ann Thorac. Surg. 48(2): 295-297 (Aug. 1989). |
| Merriam-Webster “Definition of ‘Chamber’,” O-line Dictionary 2004, Abstract. |
| Park, et al., Blade Atrial Septostomy: Collaborative Study, Circulation, 66(2):258-266 (1982). |
| Partial Supplemental European Search Report dated Dec. 11, 2018 in EP Patent Appl. Serial No. 1678939.6. |
| Roven et al., “Effect of Compromising Right Ventricular Function in Left Ventricular Failure by Means of Interatrial and Other Shunts,” American Journal Cardiology, 24:209-219 (1969). |
| Salehian et al., Improvements in Cardiac Form and Function After Transcatheter Closure of Secundum Atrial Septal Defects, Journal of the American College of Cardiology, 45(4):499-504 (2005). |
| Schmitto et al., Chronic heart failure induced by multiple sequential coronary microembolization in sheep, the International Journal of Artificial Organs, 31(4):348-353 (2008). |
| Schubert et al., Left Ventricular Conditioning in the Elderly Patient to Prevent Congestive Heart Failure After Transcatheter Closure of the Atrial Septal Defect, Catheterization and Cardiovascular Interventions,64(3): 333-337 (2005). |
| Stormer et al., Comparative Study of n vitro Flow Characteristics Between a Human Aortic Valve and a Designed Aortic Valve and Six Corresponding Types of Prosthetic Heart Valves, European Surgical Research 8(2): 117-131 (1976). |
| Stumper et al., “Modified technique of stent fenestration of the atrial septum,” Heart 89: 1227-1230 (2003). |
| Trainor et al., Comparative Pathology of an Implantable Left Atrial Pressure Sensor, ASAIO Journal, Clinical Cardiovascular/Cardiopulmonary Bypass, 59(5):486-92 (2013). |
| Zhou et al., Unidirectional Valve Patch for Repair of Cardiac Septal Defects With Pulmonary Hypertension, Annals of Thoracic Surgeons, 60:1245-1249 (1995). |
| U.S. Appl. No. 09/839,643 / U.S. Pat. No. 8,091,556, filed Apr. 20, 2001 / Jan. 10, 2012. |
| U.S. Appl. No. 10/597,666 / U.S. Pat. No. 8,070,708, filed Jun. 20, 2007 / Dec. 6, 2011. |
| U.S. Appl. No. 12/223,080 / U.S. Pat. No. 9,681,948, filed Jul. 16, 2014 / Jun. 20, 2017. |
| U.S. Appl. No. 13/107,832 / U.S. Pat. No. 8,235,933, filed May 13, 2011 / Aug. 7, 2012. |
| U.S. Appl. No. 13/107,843 / U.S. Pat. No. 8,328,751, filed May 13, 2011 / Dec. 11, 2012. |
| U.S. Appl. No. 13/108,672 / U.S. Pat. No. 9,724,499, filed May 16, 2011 / Aug. 8, 2017. |
| U.S. Appl. No. 13/108,698, filed Jun. 16, 2011. |
| U.S. Appl. No. 13/108,850, filed May 16, 2011. |
| U.S. Appl. No. 13/108,880 / U.S. Pat. No. 8,696,611, filed May 16, 2011 / Apr. 15, 2014. |
| U.S. Appl. No. 13/193,309 / U.S. Pat. No. 9,629,715, filed Jul. 28, 2011 / Apr. 25, 2017. |
| U.S. Appl. No. 13/193,335 / U.S. Pat. No. 9,034,034, filed Jul. 28, 2011 / May 19, 2015. |
| U.S. Appl. No. 13/708,794 / U.S. Pat. No. 9,943,670, filed Dec. 7, 2012 / Apr. 17, 2018. |
| U.S. Appl. No. 14/154,080 / U.S. Pat. No. 10,207,807, filed Jan. 13, 2014 / Feb. 19, 2019. |
| U.S. Appl. No. 14/154,088, filed Jan. 13, 2014. |
| U.S. Appl. No. 14/154,093, filed Jan. 13, 2014. |
| U.S. Appl. No. 14/227,982 / U.S. Pat. No. 9,707,382, filed Mar. 27, 2014 / Jul. 18, 2017. |
| U.S. Appl. No. 14/282,615 / U.S. Pat. No. 9,713,696, filed May 20, 2014 / Jul. 25, 2017. |
| U.S. Appl. No. 14/712,801 / U.S. Pat. No. 9,980,815, filed May 14, 2015 / May 29, 2018. |
| U.S. Appl. No. 15/449,834 / U.S. Pat. No. 10,076,403, filed Mar. 3, 2017 / Sep. 18, 2018. |
| U.S. Appl. No. 15/492,852 / U.S. Pat. No. 10,368,981, filed Apr. 20, 2017 / Aug. 6, 2019. |
| U.S. Appl. No. 15/570,752, filed Oct. 31, 2017. |
| U.S. Appl. No. 15/608,948, filed May 30, 2017. |
| U.S. Appl. No. 15/624,314 / U.S. Pat. No. 10,357,357, filed Jun. 15, 2017 / Jul. 23, 2019. |
| U.S. Appl. No. 15/650,783, filed Jul. 14, 2017. |
| U.S. Appl. No. 15/656,936 / U.S. Pat. No. 10,478,594, filed Jul. 21, 2017 / Nov. 19, 2019. |
| U.S. Appl. No. 15/668,622 / U.S. Pat. No. 10,463,490, filed Aug. 3, 2017 / Nov. 5, 2019. |
| U.S. Appl. No. 15/798,250, filed Oct. 30, 2017. |
| U.S. Appl. No. 16/130,978 / U.S. Pat. No. 10,251,740, filed Sep. 13, 2018 / Apr. 9, 2019. |
| U.S. Appl. No. 16/130,988, filed Sep. 13, 2018. |
| U.S. Appl. No. 16/205,213, filed Nov. 29, 2018. |
| U.S. Appl. No. 16/374,698, filed Apr. 3, 2019. |
| U.S. Appl. No. 16/395,209, filed Apr. 25, 2019. |
| U.S. Appl. No. 16/408,419, filed May 9, 2019. |
| Abraham et al., “Hemodynamic Monitoring in Advanced Heart Failure: Results from the LAPTOP-HF Trial,” J Card Failure, 22:940 (2016) (Abstract Only). |
| Abraham et al., “Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the Champion randomised trial,” The Lancet, doi.org/10.1016/S0140-6736(15)00723-0 (2015). |
| Abraham et al., “Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial,” The Lancet, DOI:10.1016/S0140-6736(11)60101-3 (2011). |
| Abreu et al., “Doppler ultrasonography of the femoropopliteal segment in patients with venous ulcer,” J Vasc Bras., 11(4):277-285 (2012). |
| Adamson et al., “Ongoing Right Ventricular Hemodynamics in Heart Failure Clinical Value of Measurements Derived From an Implantable Monitoring System,” J Am Coll Cardiol., 41(4):565-571 (2003). |
| Adamson et al., “Wireless Pulmonary Artery Pressure Monitoring Guides Management to Reduce Decompensation in Heart Failure With Preserved Ejection Fraction,” Circ Heart Fail., 7:935-944 (2014). |
| Ambrosy et al. “The Global Health and Economic Burden of Hospitalizations for Heart Failure,” J Am Coll Cardiol., 63:1123-1133 (2014). |
| Aminde et al., “Current diagnostic and treatment strategies for Lutembacher syndrome: the pivotal role of echocardiography,” Cardiovasc Diagn Ther., 5(2):122-132 (2015). |
| Anderas E. “Advanced MEMS Pressure Sensors Operating in Fluids,” Digital Comprehensive Summaries of Uppsala Dissertation from the Faculty of Science and Technology 933. Uppsala ISBN 978-91-554-8369-2 (2012). |
| Anderas et al., “Tilted c-axis Thin-Film Bulk Wave Resonant Pressure Sensors with Improved Sensitivity,” IEEE Sensors J., 12(8):2653-2654 (2012). |
| Article 34 Amendments dated May 28, 2013 in Int'l PCT Patent Appl. Serial No. PCT/IB2012/001859. |
| Article 34 Amendments dated Nov. 27, 2012 in Int'l PCT Patent Appl. Serial No. PCT/IL2011/000958. |
| Ataya et al., “A Review of Targeted Pulmonary Arterial Hypertension-Specific Pharmacotherapy,” J. Clin. Med., 5(12):114 (2016). |
| Bannan et al., “Characteristics of Adult Patients with Atrial Septal Defects Presenting with Paradoxical Embolism.,” Catheterization and Cardiovascular Interventions, 74:1066-1069 (2009). |
| Baumgartner et al., “ESC Guidelines for the management of grown-up congenital heart disease (new version 2010)—The Task Force on the Management of Grown-up Congenital Heart Disease of the European Society of Cardiology (ESC),” Eur Heart J., 31:2915-2957 (2010). |
| Beemath et al., “Pulmonary Embolism as a Cause of Death in Adults Who Died With Heart Failure,” Am J Cardiol., 98:1073-1075 (2006). |
| Benza et al., “Monitoring Pulmonary Arterial Hypertension Using an Implantable Hemodynamic Sensor,” Chest, 156(6):1176-1186 (2019). |
| Boehm, et al., “Balloon Atrial Septostomy: History and Technique,” Images Paeditr. Cardiol., 8(1):8-14 (2006). |
| Borlaug, et al., Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure, Circulation (Mar. 2022). |
| Bruch et al., “Fenestrated Occluders for Treatment of ASD in Elderly Patients with Pulmonary Hypertension and/or Right Heart Failure,” J Interven Cardiol., 21(1):44-49 (2008). |
| Burkhoff et al., “Assessment of systolic and diastolic ventricular properties via pressure-volume analysis: a guide for clinical, translational, and basic researchers,” Am J Physiol Heart Circ Physiol., 289:H501-H512 (2005). |
| Butler et al. “Recognizing Worsening Chronic Heart Failure as an Entity and an End Point in Clinical Trials,” JAMA., 312(8):789-790 (2014). |
| Chakko et al., “Clinical, radiographic, and hemodynamic correlations in chronic congestive heart failure: conflicting results may lead to inappropriate care,” Am J Medicine, 90:353-359 (1991) (Abstract Only). |
| Chang et al., “State-of-the-art and recent developments in micro/nanoscale pressure sensors for smart wearable devices and health monitoring systems,” Nanotechnology and Precision Engineering, 3:43-52 (2020). |
| Chen et al., “Continuous wireless pressure monitoring and mapping with ultra-small passive sensors for health monitoring and critical care,” Nature Communications, 5(1):1-10 (2014). |
| Chen et al., “National and Regional Trends in Heart Failure Hospitalization and Mortality Rates for Medicare Beneficiaries, 1998-2008,” JAMA, 306(15):1669-1678 (2011). |
| Chiche et al., “Prevalence of patent foramen ovale and stroke in pulmonary embolism patients,” Eur Heart J., 34:P1142 (2013) (Abstract Only). |
| Chin et al., “The right ventricle in pulmonary hypertension,” Coron Artery Dis., 16(1):13-18 (2005) (Abstract Only). |
| Chun et al., “Lifetime Analysis of Hospitalizations and Survival of Patients Newly Admitted With Heart Failure,” Circ Heart Fail., 5:414-421 (2012). |
| Ciarka et al., “Atrial Septostomy Decreases Sympathetic Overactivity in Pulmonary Arterial Hypertension,” Chest, 131(6):p. 1831-1837 (2007) (Abstract Only). |
| Cleland et al., “The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe—Part 1: patient characteristics and diagnosis,” Eur Heart J., 24:442-463 (2003). |
| Clowes et al., “Mechanisms of Arterial Graft Healing—Rapid Transmural Capillary Ingrowth Provides a Source of Intimal Endothelium and Smooth Muscle in Porous PTFE Prostheses,” Am J Pathol., 123:220-230 (1986). |
| Davies et al., “Abnormal left heart function after operation for atrial septal defect,” British Heart Journal, 32:747-753 (1970). |
| Del Trigo et al., “Unidirectional Left-To-Right Interatrial Shunting for Treatment of Patients with Heart Failure with Reduced Ejection Fraction: a Safety and Proof-of-Principle Cohort Study,” Lancet, 387:1290-1297 (2016). |
| Della Lucia et al., “Design, fabrication and characterization of SAW pressure sensors for offshore oil and gas exploration,” Sensors and Actuators A: Physical, 222:322-328 (2015). |
| Drazner et al., “Prognostic Importance of Elevated Jugular Venous Pressure and a Third Heart Sound in Patients with Heart Failure,” N Engl J Med., 345(8):574-81 (2001). |
| Drazner et al., “Relationship between Right and Left-Sided Filling Pressures in 1000 Patients with Advanced Heart Failure,” Heart Lung Transplant, 18:1126-1132 (1999). |
| Drexel, et al., “The Effects of Cold Work and Heat Treatment on the Properties of Nitinol Wire, Proceedings of the International Conference on Shape Memory and Superelastic Technologies, SMST 2006,” Pacific Grove, California, USA (pp. 447-454) May 7-11, 2006. |
| Eigler et al., “Cardiac Unloading with an Implantable Interatrial Shunt in Heart Failure: Serial Observations in an Ovine Model of Ischemic Cardiomyopathy,” Structural Heart, 1:40-48 (2017). |
| Eigler, et al., Implantation and Recovery of Temporary Metallic Stents in Canine Coronary Arteries, JACC, 22(4):1207-1213 (1993). |
| Eshaghian et al., “Relation of Loop Diuretic Dose to Mortality in Advanced Heart Failure,” Am J Cardiol., 97:1759-1764 (2006). |
| Extended European Search Report dated Mar. 29, 2019 in EP Patent Appl. Serial No. EP16789391. |
| Feldman et al., “Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure with Preserved Ejection Fraction (Reduce LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]), a Phase 2, Randomized, Sham-Controlled Trial,” Circulation, 137:364-375 (2018). |
| Ferrari et al., “Impact of pulmonary arterial hypertension (PAH) on the lives of patients and carers: results from an international survey,” Eur Respir J., 42:26312 (2013) (Abstract Only). |
| Flachskampf, et al., Influence of Orifice Geometry and Flow Rate on Effective Valve Area: An In Vitro Study, Journal of the American College of Cardiology, 15(5):1173-1180 (Apr. 1990). |
| Fonarow et al., “Characteristics, Treatments, and Outcomes of Patients With Preserved Systolic Function Hospitalized for Heart Failure,” J Am Coll Cardiol., 50(8):768-777 (2007). |
| Fonarow et al., “Risk Stratification for In-Hospital Mortality in Acutely Decompensated Heart Failure: Classification and Regression Tree Analysis,” JAMA, 293(5):572-580 (2005). |
| Fonarow, G., “The Treatment Targets in Acute Decompensated Heart Failure,” Rev Cardiovasc Med., 2:(2):S7-S12 (2001). |
| Galie et al., “2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension—the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS),” European Heart Journal, 37:67-119 (2016). |
| Galie et al., “Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses,” Eur Heart J., 31:2080-2086 (2010). |
| Galipeau et al., “Surface acoustic wave microsensors and applications,” Smart Materials and Structures, 6(6):658-667 (1997) (Abstract Only). |
| Geva et al., “Atrial septal defects,” Lancet, 383:1921-32 (2014). |
| Gheorghiade et al., “Acute Heart Failure Syndromes, Current State and Framework for Future Research,” Circulation, 112:3958-3968 (2005). |
| Gheorghiade et al., “Effects of Tolvaptan, a Vasopressin Antagonist, in Patients Hospitalized With Worsening Heart Failure a Randomized Controlled Trial,” JAMA., 291:1963-1971 (2004). |
| Go et al. “Heart Disease and Stroke Statistics—2014 Update—a Report From the American Heart Association,” Circulation, 128:1-267 (2014). |
| Guillevin et al., “Understanding the impact of pulmonary arterial hypertension on patients' and carers' lives,” Eur Respir Rev., 22:535-542 (2013). |
| Guyton et al., “Effect of Elevated Left Atrial Pressure and Decreased Plasma Protein Concentration on the Development of Pulmonary Edema,” Circulation Research, 7:643-657 (1959). |
| Hasenfub, et al., A Transcatheter Intracardiac Shunt Device for Heart Failure with Preserved Ejection Fraction (Reduce LAP-HF): A Multicentre, Open-Label, Single-Arm, Phase 1 Trial, www.thelancet.com, 387:1298-1304 (2016). |
| Hoeper et al., “Definitions and Diagnosis of Pulmonary Hypertension,” J Am Coll Cardiol., 62(5):D42-D50 (2013). |
| Hogg et al., “Heart Failure With Preserved Left Ventricular Systolic Function. Epidemiology, Clinical Characteristics, and Prognosis,” J Am Coll Cardiol., 43(3):317-327 (2004). |
| Howell et al., “Congestive heart failure and outpatient risk of venous thromboembolism: A retrospective, case-control study,” Journal of Clinical Epidemiology, 54:810-816 (2001). |
| Huang et al., “Remodeling of the chronic severely failing ischemic sheep heart after coronary microembolization: functional, energetic, structural, and cellular responses,” Am J Physiol Heart Circ Physiol., 286:H2141-H2150 (2004). |
| Humbert et al., “Pulmonary Arterial Hypertension in France—Results from a National Registry,” Am J Respir Crit Care Med., 173:1023-1030 (2006). |
| International Search Report & Written Opinion dated Nov. 7, 2016 in Int'l PCT Patent Appl. Serial No. PCT/IB2016/052561. |
| International Search Report & Written Opinion dated May 29, 2018 in Int'l PCT Patent Appl. Serial No. PCT/IB2018/051385. |
| International Search Report & Written Opinion dated Feb. 6, 2013 in Int'l PCT Patent Appl. No. PCT/IB2012/001859, 12 pages. |
| International Search Report & Written Opinion dated Feb. 7, 2020 in Int'l PCT Patent Appl. Serial No. PCT/IB2019/060257. |
| International Search Report & Written Opinion dated Feb. 9, 2022 in Int'l PCT Patent Appl. Serial No. PCT/IB2021/060473. |
| International Search Report & Written Opinion dated May 13, 2019 in Int'l PCT Patent Appl. No. PCT/IB2019/050452. |
| International Search Report & Written Opinion dated May 17, 2022 in Int'l PCT Patent Appl. Serial No. PCT/IB2022/051177. |
| International Search Report & Written Opinion dated Jul. 14, 2020 in Int'l PCT Patent Appl. Serial No. PCT/IB2020/053832. |
| International Search Report & Written Opinion dated Jul. 20, 2020 in Int'l PCT Patent Appl. Serial No. PCT/IB2020/054699. |
| International Search Report & Written Opinion dated Jul. 23, 2021 in Int'l PCT Patent Appl. Serial No. PCT/IB2021/053594. |
| International Search Report & Written Opinion dated Aug. 12, 2020 in Int'l PCT Patent Appl. Serial No. PCT/IB2020/053118. |
| International Search Report & Written Opinion dated Aug. 28, 2012 in Int'l PCT Patent Appl. No. PCT/IL2011/000958. |
| International Search Report & Written Opinion dated Sep. 21, 2020 in Int'l PCT Patent Appl. Serial No. PCT/IB2020/054306. |
| International Search Report & Written Opinion dated Oct. 26, 2007 in Int'l PCT Patent Appl. Serial No. PCT/IB07/50234. |
| Jessup et al. “2009Focused Update: ACC/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation,” J. Am. Coll. Cardiol., 53:1343-1382 (2009). |
| Jiang, G., “Design challenges of implantable pressure monitoring system,” Frontiers in Neuroscience, 4(29):1-4 (2010). |
| Kane et al., “Integration of clinical and hemodynamic parameters in the prediction of long-term survival in patients with pulmonary arterial hypertension,” Chest, 139(6):1285-1293 (2011) (Abstract Only). |
| Kaye et al., “Effects of an Interatrial Shunt on Rest and Exercise Hemodynamics: Results of a Computer Simulation in Heart Failure,” Journal of Cardiac Failure, 20(3): 212-221 (2014). |
| Kaye et al., “One-Year Outcomes After Transcatheter Insertion of an Interatrial Shunt Device for the Management of Heart Failure With Preserved Ejection Fraction,” Circulation: Heart Failure, 9(12):e003662 (2016). |
| Kaye, et al., One-Year Outcomes After Transcatheter Insertion of an Interatrial Shunt Device for the Management of Heart Failure with Preserved Ejection Fraction, Circulation: Heart Failure, 9(12):e003662 (Dec. 2016). |
| Keogh et al., “Interventional and Surgical Modalities of Treatment in Pulmonary Hypertension,” J Am Coll Cardiol., 54:S67-77 (2009). |
| Keren, et al. Methods and Apparatus for Reducing Localized Circulatory System Pressure,., Jan. 7, 2002 (pp. 16). |
| Kretschmar et al., “Shunt Reduction With a Fenestrated Amplatzer Device,” Catheterization and Cardiovascular Interventions, 76:564-571 (2010). |
| Kropelnicki et al., “CMOS-compatible ruggedized high-temperature Lamb wave pressure sensor,” J. Micromech. Microeng., 23:085018 pp. 1-9 (2013). |
| Krumholz et al., “Patterns of Hospital Performance in Acute Myocardial Infarction and Heart Failure 30-Day Mortality and Readmission,” Circ Cardiovasc Qual Outcomes, 2:407-413 (2009). |
| Kulkarni et al., “Lutembacher's syndrome,” J Cardiovasc Did Res., 3(2):179-181 (2012). |
| Kurzyna et al., “Atrial Septostomy in Treatment of End-Stage Right Heart Failure in Patients With Pulmonary Hypertension,” Chest, 131:977-983 (2007). |
| Lammers et al., “Efficacy and Long-Term Patency of Fenerstrated Amplatzer Devices in Children,” Catheter Cardiovasc Interv., 70:578-584 (2007). |
| Lindenfeld et al. “Executive Summary: HFSA 2010 Comprehensive Heart Failure Practice Guideline,” J. Cardiac Failure, 16(6):475-539 (2010). |
| Luo, Yi, Selective and Regulated RF Heating of Stent Toward Endohyperthermia Treatment of In-Stent Restenosis, A Thesis Submitted in Partial Fulfillment of the Requirements for the Degree of Master of Applied Science in the Faculty of Graduate and Postdoctoral Studies (Electrical and Computer Engineering), The University of British Columbia, Vancouver, Dec. 2014. |
| MacDonald et al., “Emboli Enter Penetrating Arteries of Monkey Brain in Relation to Their Size,” Stroke, 26:1247-1251 (1995). |
| Maluli et al., “Atrial Septostomy: A Contemporary Review,” Clin. Cardiol., 38(6):395-400 (2015). |
| Maurer et al., “Rationale and Design of the Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy Study (LAPTOP-HF),” Journal of Cardiac Failure., 21(6): 479-488 (2015). |
| McClean et al., “Noninvasive Calibration of Cardiac Pressure Transducers in Patients With Heart Failure: An Aid to Implantable Hemodynamic Monitoring and Therapeutic Guidance,” J Cardiac Failure, 12(7):568-576 (2006). |
| McLaughlin et al., “Management of Pulmonary Arterial Hypertension,” J Am Coll Cardiol., 65(18):1976-1997 (2015). |
| McLaughlin et al., “Survival in Primary Pulmonary Hypertension—the Impact of Epoprostenol Therapy.,” Circulation, 106:1477-1482 (2002). |
| Mu et al., “Dual mode acoustic wave sensor for precise pressure reading,” Applied Physics Letters, 105:113507-1-113507-5 (2014). |
| Nagaraju et al., “A 400μW Differential FBAR Sensor Interface IC with digital readout,” IEEE., pp. 218-221 (2015). |
| Noordegraaf et al., “The role of the right ventricle in pulmonary arterial hypertension,” Eur Respir Rev., 20(122):243-253 (2011). |
| O'Byrne et al., “The effect of atrial septostomy on the concentration of brain-type natriuretic peptide in patients with idiopathic pulmonary arterial hypertension,” Cardiology in the Young, 17(5):557-559 (2007) (Abstract Only). |
| Oktay et al., “The Emerging Epidemic of Heart Failure with Preserved Ejection Fraction,” Curr Heart Fail Rep., 10(4):1-17 (2013). |
| Owan et al., “Trends in Prevalence and Outcome of Heart Failure with Preserved Ejection Fraction,” N Engl J Med., 355:251-259 (2006). |
| Paitazoglou et al., “Title: The AFR-Prelieve Trial: A prospective, non-randomized, pilot study to assess the Atrial Flow Regulator (AFR) in Heart Failure Patients with either preserved or reduced ejection fraction,” EuroIntervention, 28:2539-50 (2019). |
| Park Blade Septostomy Catheter Instructions for Use, Cook Medical, 28 pages, Oct. 2015. |
| Peters et al., “Self-fabricated fenestrated Amplatzer occluders for transcatheter closure of atrial septal defect in patients with left ventricular restriction: midterm results,” Clin Res Cardiol., 95:88-92 (2006). |
| Ponikowski et al., “2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC),” Eur Heart J., doi:10.1093/eurheartj/ehw128 (2016). |
| Potkay, J. A., “Long term, implantable blood pressure monitoring systems,” Biomed Microdevices, 10:379-392 (2008). |
| Pretorious et al., “An Implantable Left Atrial Pressure Sensor Lead Designed for Percutaneous Extraction Using Standard Techniques,” PACE, 00:1-8 (2013). |
| Rajeshkumar et al., “Atrial septostomy with a predefined diameter using a novel occlutech atrial flow regulator improves symptoms and cardiac index in patients with severe pulmonary arterial hypertension,” Catheter Cardiovasc Interv., 1-9 (2017). |
| Rich et al., “Atrial Septostomy as Palliative Therapy for Refractory Primary Pulmonary Hypertension,” Am J Cardiol., 51:1560-1561 (1983). |
| Ritzema et al., “Direct Left Atrial Pressure Monitoring in Ambulatory Heart Failure Patients—Initial Experience With a New Permanent Implantable Device,” Circulation, 116:2952-2959 (2007). |
| Ritzema et al., “Physician-Directed Patient Self-Management of Left Atrial Pressure in Advanced Chronic Heart Failure,” Circulation, 121:1086-1095 (2010). |
| Roberts et al., “Integrated microscopy techniques for comprehensive pathology evaluation of an implantable left atrial pressure sensor,” J Histotechnology, 36(1):17-24 (2013). |
| Rodes-Cabau et al., “Interatrial Shunting for Heart Failure Early and Late Results From the First-in-Human Experience With the V-Wave System,” J Am Coll Cardiol Intv., 11:2300-2310.doi:10.1016/j.cin.2018.07.001 (2018). |
| Rosenquist et al., Atrial Septal Thickness and Area in Normal Heart Specimens and in Those With Ostium Secundum Atrial Septal Defects, J. Clin. Ultrasound, 7:345-348 (1979). |
| Ross et al., “Interatrial Communication and Left Atrial Hypertension—a Cause of Continuous Murmur,” Circulation, 28:853-860 (1963). |
| Rossignol, et al., Left-to-Right Atrial Shunting: New Hope for Heart Failure, www.thelancet.com, 387:1253-1255 (2016). |
| Sandoval et al., “Effect of atrial septostomy on the survival of patients with severe pulmonary arterial hypertension,” Eur Respir J., 38:1343-1348 (2011). |
| Sandoval et al., “Graded Balloon Dilation Atrial Septostomy in Severe Primary Pulmonary Hypertension—a Therapeutic Alternative for Patients Nonresponsive to Vasodilator Treatment,” JACC, 32(2):297-304 (1998). |
| Schiff et al., “Decompensated heart failure: symptoms, patterns of onset, and contributing factors,” Am J. Med., 114(8):625-630 (2003) (Abstract Only). |
| Schneider et al., “Fate of a Modified Fenestration of Atrial Septal Occluder Device after Transcatheter Closure of Atrial Septal Defects in Elderly Patients,” J Interven Cardiol., 24:485-490 (2011). |
| Scholl et al., “Surface Acoustic Wave Devices for Sensor Applications,” Phys Status Solidi Appl Res., 185(1):47-58 (2001) (Abstract Only). |
| Setoguchi et al., “Repeated hospitalizations predict mortality in the community population with heart failure,” Am Heart J., 154:260-266 (2007). |
| Shah, et al., Atrial Shunt Device for Heart Failure With Preserved and Mildly Reduced Ejection Fraction (Reduce LAP-HF II): A Randomised, Multicentre, Blinded, Sham-Controlled Trial, The Lancet, 399(10330):1130-1140 (Mar. 2022). |
| Shah et al., “Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction—5-Year Outcomes,” J Am Coll Cardiol., https://doi.org/10.1016/j.jacc.2017.08.074 (2017). |
| Shah et al., “One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (Reduce LAP-HF I) Trial—a Randomized Clinical Trial,” JAMA Cardiol. doi:10.1001/jamacardio.2018.2936 (2018). |
| Sitbon et al., “Selexipag for the Treatment of Pulmonary Arterial Hypertension.,” N Engl J Med., 373(26):2522-2533 (2015). |
| Sitbon et al., “Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience,” Eur Respir Rev., 26:160055:1-14 (2017). |
| Steimle et al., “Sustained Hemodynamic Efficacy of Therapy Tailored to Reduce Filling Pressures in Survivors With Advanced Heart Failure,” Circulation, 96:1165-1172 (1997). |
| Stevenson et al., “The Limited Reliability of Physical Signs for Estimating Hemodynamics in Chronic Heart Failure,” JAMA, 261(6):884-888 (1989) (Abstract Only). |
| Su et al., “A film bulk acoustic resonator pressure sensor based on lateral field excitation,” International Journal of Distributed Sensor Networks, 14(11):1-8 (2018). |
| Supplementary European Search Report dated Nov. 13, 2009 in EP Patent Appl. Serial No. 05703174.2. |
| Thenappan et al., “Evolving Epidemiology of Pulmonary Arterial Hypertension,” Am J Resp Critical Care Med., 186:707-709 (2012). |
| Tomai et al., “Acute Left Ventricular Failure After Transcatheter Closure of a Secundum Atrial Septal Defect in a Patient With Coronary Artery Disease: A Critical Reappraisal,” Catheterization and Cardiovascular Interventions, 55:97-99 (2002). |
| Torbicki et al., “Atrial Septostomy,” The Right Heart, 305-316 (2014). |
| Troost et al., “A Modified Technique of Stent Fenestration of the Interatrial Septum Improves Patients With Pulmonary Hypertension,” Catheterization and Cardiovascular Interventions, 73:173179 (2009). |
| Troughton et al., “Direct Left Atrial Pressure Monitoring in Severe Heart Failure: Long-Term Sensor Performance,” J. of Cardiovasc. Trans. Res., 4:3-13 (2011). |
| Vank-Noordegraaf et al., “Right Heart Adaptation to Pulmonary Arterial Hypertension—Physiology and Pathobiology,” J Am Coll Cardiol., 62(25):D22-33 (2013). |
| Verel et al., “Comparison of left atrial pressure and wedge pulmonary capillary pressure—Pressure gradients between left atrium and left ventricle,” British Heart J., 32:99-102 (1970). |
| Viaene et al., “Pulmonary oedema after percutaneous ASD-closure,” Acta Cardiol., 65(2):257-260 (2010). |
| Wang et al., “A Low Temperature Drifting Acoustic Wave Pressure Sensor with an Integrated Vacuum Cavity for Absolute Pressure Sensing,” Sensors, 20(1788):1-13 (2020). |
| Wang et al., “Tire Pressure Monitoring System and Wireless Passive Surface Acoustic Wave Sensor,” Appl Mech Mater., 536(537):333-337 (2014). |
| Warnes et al., “ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease—a Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease),” JACC, 52(23):e143-e263 (2008). |
| Webb et al., “Atrial Septal Defects in the Adult Recent Progress and Overview,” Circulation, 114:1645-1653 (2006). |
| Wiedemann, H.R., “Earliest description by Johann Friedrich Meckel, Senior (1750) of what is known today as Lutembacher syndrome (1916),” Am J Med Genet., 53(1):59-64 (1994) (Abstract Only). |
| Written Opinion of the International Searching Authority dated Apr. 7, 2008 in Int'l PCT Patent Appl. Serial No. PCT/IL05/00131. |
| Yantchev et al., “Thin Film Lamb Wave Resonators in Frequency Control and Sensing Applications: A Review,” Journal of Micromechanics and Microengineering, 23(4):043001 (2013). |
| Zhang et al., “Acute left ventricular failure after transcatheter closure of a secundum atrial septal defect in a patient with hypertrophic cardiomyopathy,” Chin Med J., 124(4):618-621 (2011). |
| Zhang et al., “Film bulk acoustic resonator-based high-performance pressure sensor integrated with temperature control system,” J Micromech Microeng., 27(4):1-10 (2017). |
| Number | Date | Country | |
|---|---|---|---|
| 20200078558 A1 | Mar 2020 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61825931 | May 2013 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 15656936 | Jul 2017 | US |
| Child | 16686013 | US | |
| Parent | 14282615 | May 2014 | US |
| Child | 15656936 | US |
